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HOOFDSTUK 1 
Data <> informatie, inleiding
Dit proefschrift is een evaluatie van methoden om het voorschrijven van artsen te
verbeteren. Hiervoor is gebruik gemaakt van de declaratiegegevens van een
zorgverzekeraar. We hebben de effecten gemeten van twee methoden om de
kwaliteit van het voorschrijven te verbeteren – namelijk een individueel gerichte
interventie (nascholing) en een groepsgerichte. Daarnaast hebben we ook de
effecten van deze interventie op patiëntniveau gemeten.
Daarvoor hebben we ons steeds de volgende vier vragen gesteld:
1. Hoe wordt gedrag beïnvloed?
2. Wat kunnen we met declaratiegegevens doen? 
3. Wat is eigenlijk goed voorschrijven? Hoe meet je dat?
4. Wat zijn effecten op patiëntniveau?
In de inleiding staan vier grote schema’s waarin de kennis die we bij aanvang van
het onderzoek hadden over de onderwerpen is samengevat. Gezamenlijk vormen zij
achtergrondinformatie voor ons onderzoek.
Diagram 1 Gedrag veranderen, kenmerken van nascholingsprojecten
In dit diagram staan op de verticale as allerlei aspecten van nascholing genoemd.
Horizontaal wordt daaraan een oplopende mate van intensiteit gekoppeld. Bij
verticaal ‘setting’, komt horizontaal ‘mass’, ‘group’ en ‘individual’. Wij denken dat
hoe meer een nascholingsmethode voldoet aan alles wat in de rechter verticale
kolom vermeld staat, hoe meer impact deze heeft. Bijvoorbeeld: Het in een grote
zaal, eenmalig presenteren van multi-interpretabele onderzoeksresultaten, waarbij
de aanwezigen niets kunnen inbrengen of vragen, zal veel minder impact hebben
dan een persoonlijk bezoek, waarin vragen kunnen worden gesteld en waarin
ruimte voor discussie is. 
Hoe persoonlijker, hoe intensiever. Toch kan het werken met een groep een aantal
voordelen bieden die één-op-één contacten niet hebben. In een groep kan discussie
ontstaan, kan iemand díe vraag stellen die een ander niet durft te stellen et cetera.
Hoe meer interactie, hoe beter informatie zal beklijven. Hoe intenser, hoe meer
bindend en hoe meer kansen om het gedrag te beïnvloeden.
Diagram 2 Declaratiebestanden in geneesmiddelen gebruiksonderzoek
Gegevens van een zorgverzekeraar zijn een administratieve weergave van wat er de
in werkelijkheid gebeurt. In dit diagram worden ‘de werkelijkheid’ en ‘de
administratieve werkelijkheid van de zorgverzekeraar’ toegelicht.
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‘De werkelijkheid’; boven de diagonale lijn:
1. De patiënt is zich bewust van een klacht en gaat naar de dokter.
2. De dokter stelt een diagnose en doet een voorstel voor behandeling, schrijft
eventueel een recept uit.
3. De patiënt besluit om naar de apotheek te gaan (of doet dat niet!).
4. De apotheker verstrekt het geneesmiddel en geeft voorlichting (of niet!).
5. De patiënt gebruikt het geneesmiddel (op een bepaalde manier).
‘De administratieve werkelijkheid’; onder de diagonale lijn. 
Apotheek en arts sturen gegevens naar de verzekeraar (HIC = health insurance
company)
a) De arts levert gegevens over de patiënt (nummer en leeftijd), de verzekeraar
betaalt het consult of het huisartsabonnement.
b) De apotheek levert gegevens over verstrekte medicijnen (patiënt, afleverdatum)
en de verzekeraar betaalt op basis daarvan de factuur. Of er voorlichting is
gegeven, is voor de vergoeding niet van belang en derhalve niet terug te vinden
in deze administratie.
De verzekeraar heeft maar een beperkt aantal gegevens nodig, dit zijn dan ook de
enige gegevens die terug te vinden zijn in zijn declaratiebestand. Deze
‘administratieve weergave’ geeft dus maar een beperkt, en niet altijd betrouwbaar,
beeld van de werkelijkheid.
Diagram 3 Wat is goed voorschrijven?
Hoe kan ‘kwaliteit van voorschrijven’ gedefinieerd worden?
Er is bij voorschrijven altijd sprake van een aantal doelen:
- Maximaal effect en minimale bijwerkingen
- Minimale kosten en de keuzes van de patiënt respecteren.
- Korte- en langetermijneffecten
Kortom: men streeft naar veilig, effectief, economisch en passend voorschrijven.
Deze doelen zijn niet altijd in overeenstemming, en vaak zelfs tegenstrijdig.
Daarnaast is het belangrijk de korte- en langetermijneffecten op een rij te zetten.
Afhankelijk van iemands verwachte levensduur kunnen deze anders wegen. Goed
voorschrijven is het afwegen van al deze doelen per individuele situatie. Het meten
van goed voorschrijven gebeurt meestal op groepsniveau en schept daarom extra
uitdagingen. 
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Diagram 4 Effecten op patiëntniveau
Het is belangrijk het effect van een behandeling op patiëntniveau te meten. De
gebruikersgroep (C) is meestal een andere dan de groep waarbij een behandeling is
onderzocht (A). Zo weten we dat de gebruikerspopulatie vaak ouder is en meer
vrouwen bevat dan de onderzochte populatie. Deze twee groepen zijn deels
overlappende deelverzamelingen van de gehele populatie (B). Uiteindelijk gaat het
echter om individuen (D) en die zijn allemaal anders.
OPZET VAN DEZE STUDIE
Deze kennis hebben we gebruikt bij het ontwerpen van het onderzoek dat in dit
proefschrift wordt beschreven. Het doel van onze studie was om methodes om
gedrag te beïnvloeden te vergelijken, waarbij declaratiegegevens gebruikt werden
om de kwaliteit van farmacotherapie te meten en te beïnvloeden. Voor en na deze
interventie hebben we vragenlijsten gestuurd naar gebruikers van antidepressiva
ouder dan 60 jaar. Omdat het gebruik van declaratiegegevens voor dit onderzoek
specifieke problemen kent gaat hoofdstuk 2 hierover. Hoofdstuk 3 beschrijft hoe we
met behulp van deze gegevens het gebruik van antidepressiva bij ouderen hebben
geanalyseerd. In hoofdstuk 4 staat beschreven welke klachten de gebruikers van
antidepressiva hadden voor de interventie begon. Hoe moeilijk het is de diagnose
depressie te stellen blijkt uit hoofdstuk 5. Om een wetenschappelijk verantwoorde
interventie te kunnen doen wilden we de artsen goed over de interventiearmen
verdelen. Wat we hiervoor hebben gedaan staat beschreven in hoofdstuk 6.
Hoofdstuk 7 beschrijft de interventie en het effect van individuele en groepsgewijze
nascholing over antidepressiva bij ouderen, bij artsen en apothekers. In hoofdstuk 8
onderzoeken we het effect van de interventie op patiëntniveau. Hoofdstuk 9,
tenslotte, gaat over de toekomst; wat kunnen grote databases met gezondheidszorg
gebruiksgegevens en de toegenomen mogelijkheden van de ICT (Informatie en
Communicatie Technologie) betekenen voor medische nascholing en onze
gezondheidszorg.
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1
Scope of the thesis
One day when he was out walking, he came to an open place in
the middle of the forest, and in the middle of this place was a
large oak-tree, and, from the top of the tree, came a loud
buzzing-noise. Winnie-the-Pooh sat down at the foot of the
tree, put his head between his paws, and began to think. 
First of all he said to himself: "That buzzing-noise means
something. You don’t get a buzzing-noise like that, just buzzing
and buzzing, without its meaning something. If there’s a
buzzing-noise, somebody’s making a buzzing noise, and the only
reason for making a buzzing-noise that I know of is because
you’re a bee."
Then he thought another long time, and said: "And the only
reason for being a bee that I know of is making honey."
A.A. Milne, Winnie-the-Pooh, 1926. 
Chapter: We are introduced, page 3.
14
INTRODUCTION
The focus of this thesis is an evaluation of methods to influence prescribing with
the aid of reimbursement data to improve the quality of pharmacotherapy. We have
not only measured the effect of our outreach program on prescribing, but also
monitored the effect on a patient level. As a result, this project addressed four main
issues: influencing behavior, the use of health insurance company data to analyze
the use of health care resources, how to define good prescribing, and measuring the
effect of an intervention on a patient level. 
Influencing behavior
The mere publication of trial results does not effectively change behavior, nor do
meta-analyses or mailing evidence-based guidelines (1-7). In times of increasing
demand for evidence-based medicine and effective use of resources, we still lack
knowledge on the implementation of innovations (8,9). How does evidence from
clinical trials and observational studies influence prescribing (10-13)? What happens
during therapeutic decision-making (14-18), how can the decision-making process
be improved, and which approaches are most effective in influencing behavioral
changes (19-21)? Intensive ways to disseminate information and facilitate
implementation are needed to achieve lasting behavioral changes (22-28).
We know that the pharmaceutical industry has a long history of effectively
influencing doctors’ prescribing behavior (29), yet non-commercial outreach
programs haven’t usually been so successful (30). What is known about outreach
programs (31,32)? Which aspects of an outreach program stimulate the diffusion of
innovations (33, 35)? How can it be most effective in improving the quality of
prescribing?
Diagram 1 describes different characteristics of outreach programs. Several different
qualities are defined on the vertical axis (4,24). The intensity of these qualities is
represented on the horizontal axis. An increase in intensity indicates more
commitment and therefore a greater likelihood of behavioral change. 
Feedback is the first quality indicated on the Y-axis. It is increasingly popular when
computerized practice support systems or reimbursement systems are being used. It
becomes more intense when immediate, like a computer reminder that pops up
every time a drug that is not in the formulary is prescribed (33). Increased
frequency of information will also make the program more intense. An outreach
program can take place within either an individual or group setting (36). Individual
contacts are more intense than group contacts, which allow one to avoid
participating. A classic one-way lecture requires less commitment than a
discussion covering knowledge, barriers to change, possible consequences et cetera.
This interaction is an important aspect of diffusion of innovations and can be
stimulated in a peer group (37).
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When the content is unapplied information, such as trial results, it is not so easy to
implement as guidelines are. Computerized decision-making trees can enforce these
guidelines. Besides the content, the uncertainty of the information is an important
aspect: a complete consensus can give a clear message whereas in most issues there
is still some discussion and some uncertainty remaining (21) (giving a third party
that is harmed by the new consensus a chance to actively frustrate the diffusion of
innovation, by presenting the information as being fuzzy.) Apart from
characteristics that are related to the content of the information, there are
characteristics that are related to how the information is presented. The medium
used for the outreach program is an opportunity to make the program more
effective; a drug bulletin is not as confronting as a personal visit. When the
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diagram 1
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educational program targets patients, schools, policymakers and paramedics as
well, the program will be more likely to change behavior than a program targeting
only one specific group (23). 
Combinations of qualities can enforce or reduce the effectiveness; feedback will be
more intense when it is immediate, personalized and more frequent. Feedback
related to clear guidelines is more interesting than overall volume or costs figures
are. In contrast, when the ball gets rolling in a group meeting, many barriers to
behavioral change may be brought up than in a one-to-one discussion. 
Academic detailing has effectively combined some of the characteristics
mentioned, improving on the pharmaceutical industry's approach towards
professionals. It consists of repeated personal visits, including feedback, presenting
clear practice-relevant recommendations and anticipating any implementation
problems (30). Not all characteristics of effective outreach visits have been
identified (23). This diagram is not intended to be complete or without any
redundancy. In the future we may discover other qualities that have a great impact
on the effectiveness of an outreach program and the diffusion of innovations. 
Apart from the above mentioned characteristics of outreach programs, quite some
legislation has been designed and implemented to influence prescribing behavior.
These laws vary from reimbursement regulations to limiting the amount of a drug
allowed per prescription. This usually will effectively change behavior, but apart
from the fact that it does not influence knowledge, it is also notorious for resulting
in (often very creative) behavior which bypasses the legislation (38). 
Analyzing reimbursement data to assess the use of health care resources
To properly use reimbursement data, we have to understand the process of data
collecting in health care and be aware of the conflicting priorities that may
influence this process. Diagram 2 simplifies some of the actions and parties
involved in this process. The process starts when a person with a complaint decides
to see a doctor (arrow 1). This doctor will then, after examining the patient, inform
her about her findings and give some advice. In more than 60% of visits this
consultation will result in a prescription (arrow 2) (39) Most patients will take this
prescription to the pharmacy (arrow 3) to get the drugs dispensed (arrow 4). Now
the patient has to decide and manage to take the drug according to the prescription
(arrow 5), which is usually referred to as compliance. The above processes are what
happens or should happen in the real world. 
The administrative systems are only a reflection of what happens in this real world
(40-42). Administration is an active process. It should be worth the effort to register
what has been done (43,44). In the case of the pharmacy, this process of
administration is rewarded because of the reimbursement requirements of most
health insurance companies and pharmacy logistics (45). Most pharmacies do not
keep records on the advice they dispense, as there is hardly an incentive to do so. 
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Physicians need to keep records as well, but in the Netherlands the financial
incentive only requires the number of patients and some social-demographic data.
For patients with public health service coverage, this fee is not influenced by the
number of consultations that actually take place. For good clinical practice, short
entries about consultations will usually be sufficient. 
When analyzing reimbursement data or other medical records, one should keep in
mind that these records are an administrative reflection of processes in health care.
The availability and appropriateness of these data for research purposes is usually
not the priority of the people who do the actual input and processing, nor of the
management. Therefore the continuity of these data suffers a great deal from
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procedural changes, political decisions, takeovers and changes in hard or software
(46,47). 
The fact that most health care is publicly funded does not only justify pharmaco-
economical analyses, it also frustrates these analyses. Minor changes in regulations
(on reimbursement or organization of health care) can have strong effects on costs
and the allocation of these costs (e.g. changing the possibilities to get a drug
reimbursed affects the prescribing volume) (48). This is in contrast to commercial
enterprises where it is (a teenyweenybit) easier to allocate costs.
How to define good prescribing
Before we can measure quality of pharmacotherapy, we have to ask ourselves what
represents good prescribing exactly? What constitutes good prescribing is not easy
to give and consequently to measure. In 1973, Parish published his oft-cited
criteria: "appropriate, safe, effective and economic" (49). This tends to imply that
there are right answers, rather than recognizing the complex trade-offs that have to
be made between conflicting goals (50). During decision-making and monitoring, it
is advisable to be aware that when we target good prescribing, there are more aims
which can also be conflicting. Barber has grouped and visualized targets as shown
in diagram 3: maximize effectiveness, minimize risks, minimize costs, and respect
the patient’s choice. This diagram clearly shows that good prescribing constitutes
balancing harm and good done to the patient by the drug, the financial
consequences of a treatment and patients’ individual differences and preferences. 
To maximize effectiveness we firstly want to alleviate a complaint or make it go
away. The best strategy to achieve this is usually defined by the interpretation of
study results. Sometimes these results are clear and unambiguous, but more often
studies give conflicting results and consensus is only reached over a period of time
as knowledge evolves. How to maximize effectiveness in treatment is therefore
subject to change over time. 
Another goal of good prescribing is to minimize risks. Here again, study results can
be conflicting and non-informative. What is considered "safe" is a very complex
(non-rational) individual decision, dependent on the beneficial effects. Risk
minimization includes hazardous events and minor transient (but possibly
uncomfortable) adverse events. 
Registered side effects are not always causal, because all medical events will be
registered in clinical trials even when they can be due to the underlying disease or
other drugs used (51).
Part of the reason why study results on the effectiveness of a treatment are so
difficult to interpret is that, when we are measuring the effects and adverse events
of a treatment, we can focus on several things: effect on the disease (complaint), life
expectancy (especially when the disease was life-threatening), adverse events or
overall well-being using quality-of-life domains. Of course, a treatment should
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firstly take away a complaint or a life-threatening condition. This goal is relatively
easy to measure for a short time period, but measuring the long-term effect of blood
pressure lowering medication on life expectancy is quite an extended project; we
therefore have added this as an extra dimension in Barber's diagram. Measuring the
extent of immediately presenting adverse events seems to be possible as well. But
to assess the long and short-term side effect load, which should include
summarizing visible and invisible adverse events, measurable and non-measurable
side effects, immediate and later effects, minor, irksome or dangerous adverse
events and those that are worse than the complaint, will not be easy. Ultimately
we want to know how the patient feels, functions and survives. 
The real aim of a medical intervention (and thus pharmacotherapy) is more than
just improving life for the patient. Usually the patient desires the treatment to
bring her back to the situation before the complaint or event ("Doctor, will I still be
able to……?"). But everything else has changed as well (we have grown older etc.). It
is usually not possible to completely return to the old situation. It is interesting to
recognize that this is what is really aimed at in our culture. ("When will I be myself
again?")
Minimizing costs and respecting patients' choices are in fact a pair of ethical
matters where we have to balance between Utilism and Kant (society and the
individual), as long as health care is funded from public resources (52). Budgets and
fundholding have created a need for "health-economics", to be able to compare
strategies (50). Assessing the costs and benefits of a (drug) treatment in financial
terms is, however, still a very complex and difficult challenge. Information we have
available on costs is usually extracted from clinical trials and can not always be
applied to daily practice. (This is true for primary study results like the
effectiveness of a drug, but is true in a stronger sense for secondary information
extracted from a trial, such as costs (28,53-56).)
Alongside ethical and economical arguments there are many practical reasons why
the patient’s choices, particularly informed choices, must be part of good
prescribing. One important practical reason to take a patient’s choice into account
is that the patient herself is going to choose whether or not to use the drug.
Disclosing important barriers to follow a certain therapy may improve compliance
and therefore the effect of a therapy. Ideally, a doctor will go through the available
evidence with the patient, and thereafter make a well-informed choice with the
patient. This kind of shared decision-making may result in the patient deciding to
live with the complaint rather than to live with the burden of a treatment.
Because good prescribing includes several goals that can be conflicting, a definition
of good prescribing is case dependent. Using this diagram helps us to communicate
the possible conflicts in individual cases. To assess quality of prescribing on a larger
scale, as often aimed at by researchers, policymakers and administrators, this
diagram might help to understand decision-making in daily practice. 
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Measuring good prescribing
Each individual case requires balancing several, possibly conflicting, goals (57). This
creates a great challenge when we are looking for criteria to operationalize rational
prescribing (58-60). We need criteria that surpass the individual level and that are
available, can be repeated, clear, comprehensible, fair and do not cause perverse
incentives (40). 
Some have developed complex algorithms to assess the quality of drug prescribing
on a patient level (61-64). These usually require indications, which are not always
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diagram 3
How to define good prescribing (chapters 3 and 8)
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available. Because all patients are different, ranking systems that can be used for
meso or macro level evaluation may become very abstract and are not easy to
comprehend or relate to daily practice (65,66).
When evaluating prescribing on a disease level, instead of on a patient level, it is
possible to choose the treatment of one condition and rank several treatments or to
measure adherence to guidelines (standardizing) (65). 
Quality of prescribing can also be evaluated on a drug level. One way is by
measuring the volume of use of agents that are generally considered to be overused
(e.g. antibiotics, expensive NSAIDs) (43). Another is to search for irrational
combinations of drugs and drugs that are not optimal for certain sub-groups (e.g.
anticholinergic antidepressants in the elderly). For our research, we chose to use a
very simple restricted measure which enabled operationalization (67). Evaluating
quality of prescribing on a drug level does not describe overall quality of
pharmacotherapy.
Measuring the effect of an intervention on a patient level
The aim of our outreach program was to change prescribing for a very specific
subpopulation, based on theoretical evidence: we asked PCPs not to prescribe
anticholinergic antidepressants to the elderly, based on research demonstrating the
vulnerability of elderly to these drugs (68-70). The primary outcome measures of
the outreach program are prevalences and incidences of antidepressant prescribing
retrieved from the reimbursement records. Thus rationalizing prescribing, the
question remains whether the patients had benefited from the intervention program
and really did feel better. There are only a few outreach programs that measure the
effect of their intervention on the patients. This is relevant because most
interventions are based on knowledge gathered from groups that have
characteristics different from those of the patients addressed in the intervention
(either directly or indirectly).
To gather information on what constitutes good prescribing we have to compare
and interpret the effect of several treatments on groups of patients (71). Applying
that treatment to another subpopulation or one specific individual will probably
give different results from the treatment on the study population. Not rarely,
relations are revealed that apply only for specific subpopulations of patients. We
have to realize that the effectiveness for other (sub)groups remains unclear
(57,72,73).
Diagram 4 demonstrates how research populations (A) can differ from consumer
populations (C). A typical clinical trial population includes only fit male adults.
The effect of a drug applied to the consumer population (which does not necessarily
equal the targeted population), will therefore probably differ from the effect in the
research population. The same can happen when study results are extrapolated to
the total population or when the effect on a specific individual is expected to be
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equal to that on the research population. This is a dilemma for doctors,
policymakers and patients as well. New research techniques try to tailor treatment
results by defining subpopulations in each treatment group, but no subgroup is an
individual with all her individual characteristics. 
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diagram 4
The effect on a patient level (chapters 4 and 8)
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OBJECTIVES AND OUTLINE OF THIS THESIS 
Given what we know about the quality of pharmacotherapy, we set out to
investigate methods to change prescribing, using reimbursement data to assess
quality and to influence it. Before and after the intervention we sent out
questionnaires to users and former users of antidepressants in order to be able to
evaluate the effect of the academic detailing program on a patient level. 
As we made extensive use of reimbursement data, we had to start examining the
possibilities to perform research with these data, which had been collected for
another purpose. This is described in chapter 2. We then used these data to define
an area of suboptimal prescribing to target in our intervention. The prevalence and
incidence of anticholinergic and non-anticholinergic antidepressant use in the
elderly, as described in chapter 3, was in our opinion a relevant and suitable topic
for the intervention. To be able to measure the effect of the intervention on the
targeted population of antidepressant users we needed to send out a questionnaire
to the over-sixty users of these drugs, including questions covering quality of life,
complaints and medical consumption, mood and some basic statistics. One
questionnaire was sent before and one was sent after the outreach program. The
adverse events, possibly due to antidepressants, mentioned by this group prior to
the intervention are described in chapter 4. As treatment starts with diagnosis,
chapter 5 compares various scales to score depression in our research population. 
The outreach program was designed as a three-armed intervention (group approach,
individual approach and a control arm) to evaluate the effect of two different
approaches to influence the prescribing of PCPs: the impact of individual visits vs.
group visits, both with the use of academic detailing techniques. As in the
Netherlands PCPs and pharmacists work together in Peer Review Groups (PRGs) to
improve the quality of pharmacotherapy, we took these groups as the unit of
randomization. To be able to balance relevant characteristics of these groups over
the treatment arms, we took an inventory of characteristics of these groups prior to
the intervention. This inventory and the stratification of the PRGs is described in
chapter 6. The aim of this intervention was to make general practitioners more
aware of the vulnerability of elderly for the anticholinergic adverse events of most
TCAs. The effect of this outreach program on the incidence of anticholinergic
antidepressants in the elderly is described in chapter 7. Chapter 8 assesses the effect
of the intervention on a patient level. Chapter 9 comprises the summary and final
considerations. It describes what continuous medical education might look like in
the future, and the role of very large medical information databases in quality
assessment and continuous education. It aims to stimulate thinking and working
on the implications of ICT (Information and Communication Technology) on
health care. 
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HOOFDSTUK 2
Passen de onderzoeksdoelen bij de beschikbare gegevens? Een checklist om dit
systematisch na te gaan
Een schat aan gegevens, maar ook een goede onderzoeksbron?
Zorgverzekeraars voeren een uitgebreide administratie, bijvoorbeeld om de
declaraties van apothekers en huisartsen te verwerken, en om verzekerden te
registreren. Op deze manier bouwt een verzekeraar verscheidene, vaak enorme
gegevensbestanden op: databases. Het is verleidelijk te denken dat je met een
dergelijke verzameling gegevens onderzoek zou kunnen doen naar veel
onderwerpen. In dit hoofdstuk is een methode beschreven om te beoordelen of een
database geschikt is voor een specifieke onderzoeksvraag. Of dat zo is, hangt af van
de gegevens in de database en van het onderzoeksdoel. 
De ideale database
Als eerste stap hebben we gedefinieerd hoe ‘de ideale database’ voor farmaco-
epidemiologisch onderzoek eruit zou moeten zien. In de ideale database is in
principe álles opgenomen. Alle gebeurtenissen zijn zoveel mogelijk in detail
vastgelegd: de arts, de patiënt, de laborant die heeft geprikt en de uitslag van de
bloedtest, het geneesmiddel dat werd voorgeschreven, de apotheker die het
verstrekte, de informatie die zij gaf enzovoorts. Iedere patiënt, iedere behandelaar,
kortom iedereen die betrokken is bij de zorg, is uniek te identificeren. In de ideale
database zijn de gegevens niet gegroepeerd, maar apart opgeslagen. De ideale
database heeft een oneindige historie, en de structuur waarin de gegevens zijn
verzameld verandert nooit. Aan de ene kant wil je dat de gegevens optimaal zijn
beveiligd, aan de andere kant is goede toegankelijkheid een belangrijke vereiste (en
dat is natuurlijk tegenstrijdig). Een ideale database is verder goed en foutloos aan
andere bestanden te koppelen. En ten slotte: de gebruikte hard- en software mogen
niet veranderen. 
De ideale database bestaat dus niet: deze zou te onhandelbaar, te star en door
niemand te onderhouden zijn. Een database wordt altijd gebouwd met een doel. De
gebruiker wil bepaalde gegevens kunnen terugvinden, gebruiken of bewerken. Hoe
een database eruit ziet, is daarvan het gevolg.
Vergelijking
De database die wij voor ons onderzoek gebruikten, was een declaratiebestand van
OZ-zorgverzekeringen. Dit gegevensbestand bevatte declaraties van apothekers voor
de geneesmiddelen die aan ziekenfondsverzekerden waren verstrekt op recept van
de huisarts. Het bleek voor een niet-ingewijde bepaald niet makkelijk om de
benodigde gegevens te ontrafelen.
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We hebben ‘onze’ database vergeleken met de ‘ideale’ database. Hiervoor
ontwikkelden we een tabel (tabel 1) waarmee het mogelijk is een database
systematisch te onderzoeken op de geschiktheid voor een bepaald onderzoeksdoel.
Uit die vergelijking bleek dat op basis van ‘onze’ database veel onderzoek wél
mogelijk is, maar ook heel veel niet. In de declaratiebestanden was de code van de
verstrekte geneesmiddelen opgenomen, plus de datum van levering, de naam van de
apotheek, de naam van de patiënt en de code van de huisarts die het middel had
voorgeschreven. Omdat de verzekeraar deze gegevens verzamelde met het doel
betalingen te verrichten, was het aannemelijk dat ze zeer betrouwbaar en compleet
waren. De gegevens hadden een historie van een paar jaar; oudere gegevens waren
door veranderingen in hard- en software moeilijk te achterhalen. Over patiënten
kon aanvullende informatie opgeroepen worden. Van de huisartsen was de naam te
traceren in een papieren dossier.
Maar op een aantal vragen gaf de database uiteraard geen antwoord. Gaf de
apotheker voorlichting bij het verstrekken van de medicijnen? Gebruikte de patiënt
de geneesmiddelen wel goed? Welke medicijnen zijn voorgeschreven door een
specialist?
Uit de analyse bleek dat we door middel van de declaratiebestanden wel goed zicht
konden krijgen op wat wordt voorgeschreven in de eerste lijn, maar van wat in de
tweede lijn gebeurt weten we veel minder. 
CONCLUSIE
De methode die we ontwikkelden om databases te analyseren op geschiktheid voor
farmaco-epidemiologisch onderzoek, kan ook worden gebruikt door anderen die een
dergelijk onderzoek willen beginnen of moeten interpreteren.
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Do the research goal and databases
match? A checklist for a systematic
approach
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Suddenly Christopher Robin began to laugh…and he
laughed…and he laughed…and he laughed. And while he was
still laughing – Crash went the Heffalump’s head against the
tree-root, Smash went the jar, and out came Pooh’s head
again…
A.A. Milne, Winnie-the-Pooh, 1926. 
Chapter: piglet meets a Heffalump, page 64.
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Abstract
To test the appropriateness of a given database for
specific research questions, we designed a checklist
starting with the definition of an ideal database. This
ideal database contains all relevant data on patients,
providers and services. It is safe and accessible, input is
always accurate, continuity is guaranteed and linkage
with other information is easy. These features are often
taken for granted, but are highly influenced by
organizational processes in health care and
prioritization. Starting with the characteristics of an
ideal database, one can systematically list the required
aspects for research goals and compare these with the
available systems. This checklist can also be valuable to
others to design or interpret studies based on claims
databases. 
Keywords: pharmaco-epidemiology, drug-utilization,
record-linkage, benchmarking, reimbursementdata,
administrative aids
INTRODUCTION
Due to the increased computerization of administrative work, a tremendous
amount of health care data has become available for research in the last decades.
Health insurance companies (=HICs) maintain administrative databases originating
from systems that provide or finance medical care and contain computerized
records of encounters between patients and health care providers (1). These so-
called claims data (also known as reimbursement records or insurance data) contain
information about patients, providers and their encounters. Claims data are
increasingly used for drug utilization reviews, epidemiological research,
policymaking and to support management (2-7). As HICs register the medical
consumption of large numbers of people, the utility of these data is potentially
enormous. One focus in the analysis of these databases is suboptimal prescribing.
This is an issue of recurrent concern of many researchers and policymakers (8-11).
With the availability of a wide variety of drugs and with the ongoing knowledge of
effectiveness and the detection of new adverse drug reactions, the increasing
demand for "evidence based medicine" and limited resources in health care, the
analysis of quality of prescribing through these databases is of growing interest (12). 
Researchers have been using these databases for decades now and are still
discussing the potency and pitfalls of using these data for drug utilization studies
(1,2,5,13). We have designed an approach to match research goals with the qualities
of a database. Claims data research design is often a process of balancing research
question and available data (figure 1). 
Figure 1: qualities of a research database
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This process can be improved when using a checklist on an "ideal" database (table
1). Using this method, relevant qualities of databases will be taken in account.
"Blueprint" assumptions about databases will be made explicit. It makes possible a
systematic analysis of what is available and the discrepancies between different
goals.
We use this method below to discuss whether a Dutch HIC (HIC-OZ: Health
Insurance Company- Mutual Care) data set can be used to assess quality of
prescribing. The required and available databases have been compared with the aid
of this checklist, and the differences will be discussed. This method can be used by
others to make inventory of the required and available data.
AN IDEAL DATABASE
Ideal: Research Goal
For each goal and each research question a different set of data is required, and
other relations (between the data) need to be revealed. Furthermore, the necessary
accuracy is dependent on the goal; resource planning requires a different degree of
accuracy than does research on adverse (drug) reactions, where a one-in-a-million
occurrence can be relevant. An ideal database can be used for scientific research,
policymaking, resource planning, fraud control, benchmarking and so on.
Ideal: Data on Encounters
An ideal database for research provides the opportunity to follow persons (patients
and providers) in time and registers all medical encounters and the identity of the
provider(s) involved (table 1). This means a unique code is needed to identify
persons. This code should not be subject to change, not in time and not between
different sets of data. Alternatively, clear mapping must be provided to relate old
codes to new ones. It must be possible to relate all medical services to a person and
it must be unambiguous what service has been provided to whom and by which
provider. An ideal research database gives the opportunity to relate to as many
patient characteristics as needed. Depending on the research question one might
also be interested in education, smoking attitudes and other health behavior,
occupation, family relation or even sexual preference or gene mapping. Ideally, all
health care providers (whether individual, clinic, hospital or other institutions) are
uniquely identifiable and details about them are computerized.
An ideal database contains all relevant details about health care services
(procedures), including details on results, diagnoses, time, place, costs and of course
which patient and health care provider were involved. Encounters can result in
more services ordered, possibly including other providers and procedures (referral).
Each procedure needs a unique code and each diagnosis must be clear and includes
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information on the severity of the disease. Relations between code numbers and
disease entities should be evident through clearly defined mutually exclusive
categories (14). Clustering is loss of information. The ideal database can be a
collection of databases that are feasible for record linkage.
Ideal: Other Qualities
Other aspects of an ideal database include security, accuracy and continuity. An
ideal database is safe; non-authorized persons should not have access to personal
information. To assure safety advanced technology and procedural steps are needed.
Despite advanced technology, there will always be a conflict between security and
accessibility. Society will have to discuss the advantages of these databases to
improve health care and find ways to avoid an invasion of privacy that might ensue
as a byproduct (15,16). The ideal database is completely accurate; all input,
independent of location, computer system or interpreter, is similar. All input
should be swift and impeccable. Nothing should jeopardize continuity. All details
and history are kept indefinitely. In this ideal database, all registrations can be
linked smoothly. Prerequisites to realize linkage are proper coding and
compatibility of computer systems.
REQUIRED FOR RESEARCH ON QUALITY OF PRESCRIBING
Required: Research Goal
Quality of prescribing means prescribing the right substance (in the correct dose,
duration and form) for the right indication, with adequate information and
instruction to the right person (WHO) in accordance with co-morbidity and other
medication used. In 1973 Parish summarized the features of rational prescribing as
appropriate, safe, effective and economical (10). 
Required: Data on Encounters
For many forms of pharmaco-epidemiological research, unique codes to identify
users and prescribers are needed (table 1). Details on the pharmaceutical products,
costs, doses, duration and form are necessary. Information on indication and
instructions provided is also desired. To evaluate appropriate prescribing it is
required to know other patient characteristics, e.g. pregnancy, allergies, complaints
and diseases, non-reimbursable medication used and non-pharmaceutical (para-)
medical interventions. When prescribing was not according to protocol, the reason
for this should be known.
Required: Other Qualities
The researcher desires good and swift access to all relevant information and does
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not have a primary interest in security. Data relevant for research on the quality of
prescribing should be completely accurate and computerized. All input should be
up-to-date. An extended history needs to be available, preferably in the same
format. Linkage between databases containing information on patients, providers
and pharmaceutical products is necessary. Linkage with other services and
diagnoses can be relevant to estimate the effect of different treatments on the use
of other resources (e.g. physiotherapy or hospitalization) (17).
DATA AVAILABLE AT A DUTCH HEALTH INSURANCE COMPANY
Available: Goals
Claims data are primarily gathered for reimbursement purposes. This has to be
done according to certain laws and regulations. Yet, the reality is that where
prescriptions are handled, goals can conflict with each other. In pharmaceutical
practice, for example, conflicting interests are: helping patients swiftly and
accurately, and entering the right information, processing information for
reimbursement, or for drug review. This is reflected in accuracy. At an HIC,
conflicting goals can exist between several units. The financial department focuses
on prompt payment, which contrasts with the goal of internal auditing, which is
clear insight in processes. Account managers want a good relationship with the
providers of care, but also want to prevent unnecessary reimbursements. Marketing
wants as many customers as possible. Management wants information for
policymaking. In addition, researchers want all data to be clean and accurate, easily
accessible, linkable etc., allowing for all possible questions to be addressed (table 1).
Available: Data on Encounters
HICs keep family or personal codes for the insured population, a family number
being sufficient for most reimbursement goals. Combining a family number with
the date of birth and sex will identify most individuals, but will fail to recognize
same-sex twins and all other multiple births. Next to that, the need to combine
information creates an opportunity for errors. HIC-OZ registers personal details
such as address, employer, occupation (not the history of these), religion, income
and family structure. 
Most health care providers in the Netherlands (including doctors and pharmacists)
have a personal code. These codes are unique, not subject to change and are
maintained at a national level. The practices and institutions where they work in
also have a code of their own. This does not mean that all claims data contain the
right provider code. In hospitals, the department head is often the provider whose
code is used. Also, in primary care group practices and rota groups, codes can be
used in several ways (for example, the doctor seen or the usual family doctor).
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When a health care provider from outside the area is involved (not to mention
locums and trainees), there is an increased chance the code used is not the
legitimate personal code. Detailed information on the providers themselves
(address, on-call group, age, university, training or special interests) is only partly
available at HIC-OZ, most of which was not automated.
Data on procedures vary depending on the type of service. Reimbursement records
on medication contain very detailed information, including the patient and provider
codes, the pharmaceutical product, the form, amount and costs, the prescribed daily
dose, and the time of dispensing (17). They do not include an indication or
diagnosis, nor do they contain information on instructions given. 
Available: Other Qualities
Security and access are organized and access is limited to a restricted number of
people. Accuracy is strongly related to the goal of data collection –in everyday life
people are often forced to set priorities. "The relationship of the claims to
reimbursement can be both a blessing and a curse. The blessing is that such linkage
ensures that diagnoses and procedures will in fact be recorded so the provider will
be paid. The curse is that what is recorded may be merely enough to satisfy the
minimal requirements for getting paid, or can even skew what is recorded so as to
maximize cash flow rather than nosological purity." (5)
Input and maintenance in the real world are a product of many conflicting interests
between and within organizations, endangering flawless input and maintenance (15)
(18). In the Netherlands, information on medication is gathered and processed on a
monthly basis and back-up tapes are available for at least five years. Because of the
financial incentive to register all prescriptions, only a few will be missing. On the
other hand, the same incentive only requires that the prescription is reimbursable.
This requires no more than a valid insurance number, an existing doctor and a
reimbursable item with a code and price that match (5). Extremes will be noted by
the administrators, but it is hard to check which child needed the prescription and
which doctor was actually the prescriber.
Takeovers or consolidation of companies and new developments in hard or software
jeopardize continuity on a large scale. When companies merge, information
technology is seldom a priority issue. Companies usually take over an existing
system from one of the companies, or new systems are implemented. Continuity of
data is further endangered by new legislation (e.g. shift from prescription-only to
OTC drug or changing laws on reimbursement). Information on personal medical
consumption is troubled when people change their HIC. This usually means that
all data concerning them will be gathered in other databases at a different location,
using another structure and other personal codes.
In most reimbursement databases, linkage is possible as most codes are unique, but
troubled by hard and software incompatibility and minor differences in coding.
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RESULTS COMPARING REQUIRED AND AVAILABLE DATABASES
Results: Goals
There are important differences between the research goal and the goal of data
gathering at a HIC (table 1). For research on the quality of prescribing, very exact
information on decision making and advice giving is needed. At a health insurance
company, research is not the first goal of data collection. The reason that HICs
gather these data is to allocate financial resources in health care. For
reimbursement purposes it is not always relevant who did what, why, how, how
often, and to whom. Bulk payments diminish administrative load and therefore
save money, but do not serve researchers.
Results: Data on Encounters
Most people are uniquely identifiable, but researchers will not be able to track
multiple births. When people change their HIC, they are usually out of sight of
researchers. Most research needs providers to have unique personal codes. In group
practices and during night calls there is quite some inadequate coding of actual
prescribers. Details on form, dosage, costs and duration are available for
researchers. Required information on a diagnosis or an indication for treatment is
not available at a Dutch HIC, this can partly be retrieved by interpreting the
medication history. Next to that, it is not known whether instructions for use have
been given adequately or interpreted satisfactorily. 
Results: Other Qualities
Data are not always easy to access and decipher for researchers, due to procedures
and technical obstacles. Security is usually not an obstacle for authorized
researchers. 
Researchers prefer computerized data that are completely accurate, but accuracy is
a problem in reimbursement data, partly due to conflicts of interest and putting
priories. 
Although back-up tapes are usually available to go back in time, this does not make
historic information easily accessible due to incompliant computer systems and
modified architecture. Research on quality of prescribing requires linkage of
pharmacy records, patients and providers. This is possible with HIC-OZ data.
Linkage with other resources (hospitalization, physiotherapy) is troublesome. 
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DISCUSSION
HIC data are a very good potential source for information on the use of health care
resources and its outcomes. The direct linkage between drugs prescribed and
prescribing physician offers the unique opportunity to examine physician
prescribing patterns as well as patterns of recipient drug consumption. To extract
information quite some issues have to be solved. Even within the primary process
there are conflicting goals that have to be taken into account. Other problems
concern the records themselves: they are not always what they seem. HIC have
information available on the reimbursement of prescription drugs. Researchers and
policymakers have to be aware that prescription drugs are firstly prescribed,
secondly dispensed, then reimbursed. When a prescription is reimbursed, this does
not necessarily mean that the right person is going to use the drug according to the
instructions given (not to mention inter-individual differences in
pharmacokinetics).
Moreover, the relevance of some details may change in time, new knowledge will
create the need for other data. Therefore the answer to what is relevant will always
be temporary.
Other issues concern the subjects of this information: patients and providers. How
can society balance benefit and harm possibly done to them by the exploration of
these data? Security and accessibility will always have to be balanced. Individual
and social benefits and risks have to be weighed, after intensively examining short-
and long-term consequences -a political issue. It might bring society to the
conclusion that we do not want to keep all personal information in automated
databases, whatever the potential benefits, whatever the safety procedures. Personal
integrity has to be respected. Privacy should always be respected and data treated
accordingly. Researchers should also respect security measures and not attempt to
override them because of the importance of their research.
Continuity of data rarely receives enough attention. It is not a priority issue, but
seems to be a problem that can be solved with technical and financial effort, like
maintenance and swift input. Each goal and each process requires its own data
architecture and data cleaning, therefore, each goal takes time and money of its
own. This is also reflected in the back-up sets that are made. Most serve a specific
goal. The more specialized the function of the (back-up) set, the less universally it
can be used. Back-up sets take time to make and space to keep; therefore
management and the IT department have to be convinced of the usefulness of each
set. If goals are being balanced in a different way (e.g. due to management changes),
this can be reflected in the databases. A change in the databases, whether minor or
large, can jeopardize continuity of the data (19). 
This approach provides a systematic approach for matching research goals and
available data. Despite that the aspects mentioned are strongly entwined, this
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checklist can help others to analyze the appropriateness of available data for their
research goals. The systematic analyses of research question and available data
through the use of a checklist on an ideal database will give better insight in the
potencies and pitfalls of the databases.
Architecture, language, hard and software, and the frequency of registrations are not
discussed in detail here. In an ideal database they are not relevant, but in reality
can be important obstacles that have to be overcome. The relevance of some
inadequacies in the databases can be increased or solved because of the above-
mentioned aspects. For example, small errors in input can increase dramatically in
magnitude depending on the number of linking and converting phases needed.
Moreover, there is still lack of algorithms to identifying good prescribing using
claims databases. What is the standard of rational prescribing? Simply listing
profiles or ranking volumes and a distribution of providers according to these do
not equal quality of care. There is a tendency to label heavy prescribing as inferior
prescribing, but these measurements have limited value to help patients obtain the
right drug in the right amount at the right time (15). Drug-drug incompatibilities
per topic are relatively simple to assess. Analyses of certain types of patient drug
profiles manifest utility. Yet meaningful interpretation still requires application of
certain criteria. The design and validation of methods to assess quality of drug
prescribing are still a field of quite some research (20, 21).
In conclusion, the use of a checklist on an ideal database for claims data research is
a valuable tool in the design and evaluation of pharmaco-epidemiological research.
Researchers, HICs, and policymakers should be aware of the potencies and pitfalls
of these valuable sources and deal with them accordingly (22). At this moment, a
substantial amount of claims data research is being done. In the future, the
assessment of the quality of care will become increasingly important due to the
increasing need for better understanding of the process and results of health care.
The increasing role of claims data for research can be supported by the systematic
analyses of the appropriateness of these databases for different research questions.
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HOOFDSTUK 3
Het gebruik van prevalentie-  en incidentiegegevens om de invloed van leeftijd
op het voorschrijven van antidepressiva met en zonder anticholinerge effecten
te onderzoeken
‘Oude’ en ‘nieuwe’ antidepressiva
We hebben in de gegevens van de zorgverzekeraar naar een gebied gezocht  waar de
kwaliteit van voorschrijven verbeterd zou kunnen worden. Op dat gebied wilden we
een interventie doen – letterlijk: een ‘tussenkomst’ –  met het doel die kwaliteit te
verbeteren. Met andere woorden: een actieve poging doen om het voorschrijfgedrag
van artsen te veranderen.
Op het moment van studie was er een discussie gaande over de vraag  wat de beste
antidepressiva zijn: de ‘nieuwe’ antidepressiva of de ‘oudere’ antidepressiva. De
‘nieuwe’ zijn duurder dan de ’oudere’, een niet onbelangrijk gegeven in de discussie
rondom het geneesmiddelenbeleid.
Tegelijkertijd speelde er een discussie over de bijwerkingen van de zogenaamde
anticholinerge geneesmiddelen. Ouderen blijken hiervoor veel gevoeliger te zijn dan
jongere mensen. Tot de belangrijkste sterk anticholinerge geneesmiddelen horen
een paar van de ‘oude’ antidepressiva.
Een rationele keuze?
Op basis van deze feiten stelden we vast dat het rationeel zou zijn als bij ouderen
alle sterk anticholinerge middelen zouden worden vermeden. We hebben
onderzocht of deze redenering bevestigd werd in de gegevens van de
zorgverzekeraar. Klopte het dat aan oudere patiënten minder vaak een sterk
anticholinerg middel werd voorgeschreven dan aan jongere? Om dit te onderzoeken
hebben we in de database de patiënten geselecteerd die antidepressiva slikten. Na
vergelijking van jongere en oudere gebruikers van antidepressiva bleek dat aan
oudere mensen juist méér anticholinerge middelen werden voorgeschreven. In de
grafieken is dit duidelijk te zien. De donkere kolommen betreffen de sterk
anticholinerge middelen. Het gebruik hiervan neemt toe met de leeftijd, terwijl het
gebruik van minder anticholinerge middelen (lichte kolommen) eerder afneemt.
Nieuwe gebruikers
Als mensen al langere tijd een geneesmiddel slikken, en daar tevreden over zijn, is
het voor een arts niet gemakkelijk hen te overtuigen dat een nieuw, ander middel
beter is. Vaak zal een arts kiezen voor voortzetting van de bestaande medicatie.
Daarom hebben we niet alleen naar bestaande gebruikers – prevalentie – gekeken,
maar ook naar nieuwe gebruikers – incidentie. We hebben gekeken naar ouderen
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aan wie, voor het eerst of na een interval van ten minste zes maanden, een recept
voor antidepressiva werd uitgeschreven. 
Dit zogenaamde incidente voorschrijven is een belangrijk beslismoment; hier
maakt de arts opnieuw afwegingen. Wat schreven artsen voor aan patiënten die
voor het eerst een antidepressivum kregen? Oude mensen bleken ook bij nieuwe
(incidente) recepten vaker een anticholinerg middel te krijgen.
CONCLUSIE
Uit het voorgaande blijkt dat aan het voorschrijfbeleid van antidepressiva aan
ouderen inderdaad wat te verbeteren leek. Daarom werd dit het onderwerp voor
onze interventie.
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The use of prevalence and incidence
measures to describe age related
prescribing of antidepressants with and
without anticholinergic effects
A modified version has been published in 
the Journal of Clinical Epidemiology 53 (2000) 645-651
Martine E.C. van Eijk, Priya Bahri, Gert Dekker, 
Ron M.C. Herings, Arijan Porsius, Jerry Avorn, 
Anthonius de Boer
"Pooh," he said, "where did you find that pole?"
Pooh looked at the pole in his hands.
"I just found it," he said. "I thought it ought to be useful. I just
picked it up."
"Pooh," said Christopher Robin solemnly, "the Expedition is
over. You have found the North Pole!"
"Oh!" said Pooh.
A.A. Milne, Winnie-the-Pooh, 1926.
Chapter: Expotition to the North Pole, page 113.
Abstract
To evaluate whether physicians avoid the prescribing of
highly anticholinergic antidepressant (highly AAD) in
the elderly, a population-based retrospective data
analysis was performed, using databases from a Dutch
health insurance company. Data collected on
approximately 240,000 persons covered the period from
1 July 1993 to 1 January 1996. The prevalence and the
incidence (number of new starters) of antidepressant use
was measured over 1994 and 1995. Use of highly AAD
was proportionally higher in the elderly in terms of both
prevalence and incidence rates; the ratio of starters of
highly AAD versus starters of less AAD in 1994
increased steadily with age (from 0.54 in the age-group
20-29 to 1.15 in the age-group 60-69). In 1995 these
incidence ratios decreased (0.41 to 0.99, respectively);
however, the decrease was higher in the younger age
groups.
The data indicate that in the population studied,
physicians do not refrain from prescribing highly
anticholinergic agents to older patients despite their
potential adverse drug reactions in this age group.
Moreover, this study indicates that prevalence and
incidence rates can be extracted from reimbursement
data and give insight into actual prescribing practices.
Keywords: antidepressive agents, aged, drug utilization
(review), pharmaco-epidemiology, prevalence and
incidence
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INTRODUCTION 
Quality of prescribing has become more and more an issue of concern for policy
makers and health insurance companies. To use resources more efficiently, the
process of prescribing is increasingly subject to various types of quality assurance
activities. Analyses of prescription data can provide the basis for reviewing pre-
scribing practices and developing measures to promote the rational use of drugs and
to avoid drug-related problems (1). We used prescription data at a health insurance
company (HIC) level to identify and characterize areas of suboptimal prescribing.
One group of drug-related problems of special interest is the category of
anticholinergic side effects. These include dry mouth, blurred vision, constipation,
urinary dysfunction, hypotension, tachycardia, and cognitive impairment (2,3)
which all reduce the patient’s quality of life and can cause substantial morbidity
and even mortality. Among the agents with these adverse reactions, antidepressants
are important because of their high levels of consumption, their increasing use and
the availability of alternatives with a more favorable side effect profile.
Antidepressants are prescribed in elderly patients to a great extent (4,5). The elderly
are marked by a higher sensitivity to anticholinergic effects which might worsen
pre-existing symptoms (6-11). Some authors therefore recommend avoiding the use
of highly anticholinergic agents in the elderly completely (12-15). Recently, in the
Netherlands, two consensus reports on the treatment of depression have been
published. The consensus report published on behalf of the Dutch association of
general practitioners ('NHG-standaard'), concludes that the serotonine re-uptake
inhibitors (SSRI) are not superior in term of efficacy, but more expensive. Therefore
the tricyclic antidepressants amitriptyline and imipramine are recommended as
first choice drugs in the treatment of depression (16). In contrast, the consensus
report on the treatment of depression which was prepared by consultants of
different disciplines (psychiatrists, geriatricians etc.), places the selective serotonin
re-uptake inhibitors as first choice compounds (17). They conclude that for
ambulant patients these are safer and better tolerated. In neither report is age
presented as a criterion in clinical decision-making. It is not yet known to what
extent physicians in the Netherlands avoid the prescribing of antidepressants with
anticholinergic effects in elderly patients.
Most drug utilization studies evaluate plain volumes of drug use (number of
prescriptions, DDD, costs) instead of measures on a patient level (how many people
are on the drug and how many people have started the drug).
The aim of this study was to evaluate the prescribing of antidepressant with or
without highly anticholinergic effects in different age groups, using prevalence and
incidence measures, in order to evaluate to what extent physicians consider the
risk of anticholinergic drug reactions in elderly patients when prescribing an
antidepressant.
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MATERIALS AND METHODS
Prescription Data
The data used for this study were obtained from the Dutch HIC "OZ
zorgverzekeringen" and consisted of complete drug dispensing histories of a defined
population from 1 July 1993 to 1 January 1996. The population consisted of 98% of
those in the South Holland islands area who were required by law to be insured
under the national health insurance system (the so-called "Sickness Fund"). The
Sickness Fund insures the lower income brackets comprising approximately 65% of
the population of the Netherlands.
The data were collected in the pharmacies and sent to the health insurance
company on either diskette or magnetic tape for the purpose of reimbursement.
Back-up tapes of the reimbursement system were used for this research. The data
did not include the patient’s name, but gave the family insurance number, the date
of birth and sex. This information was used to combine prescription records so that
individual medication histories could be obtained. The drug-related information
consisted of the drug identification number, the dispensing date, the number of
units dispensed and the prescribed daily dose.
Drug Classification
The antidepressants were classified with regard to their in vitro and in vivo
anticholinergic effects. This classification was based on standard literature (3,18,19)
and a literature review on anticholinergic side effects (8,20-23). In addition, the
evaluations as published in the Dutch National Formulary ('Farmacotherapeutisch
Kompas' by the Health Insurance Executive Board) were used, as this reference
book is the most frequently consulted formulary in the Netherlands.
The following agents marketed in the Netherlands were classified as highly
anticholinergic antidepressants (highly AAD): amitriptyline, clomipramine,
doxepin, imipramine, trimipramin and maprotiline. Although there is some
controversy in the literature about the anticholinergic effects of maprotiline, this
compound was nevertheless included as it is classified as highly anticholinergic in
the Dutch National Formulary. All other agents belonging to the group of
antidepressants according to the ATC classification were classified as causing fewer
or no anticholinergic effects and were called less anticholinergic antidepressants
(less AAD).
Prevalence and Incidence Measures
The extent of prescribing of highly AAD versus less AAD was determined by
calculating the prevalence and incidence of drug exposure by age group. Prevalence
represents the proportion of patients treated by an antidepressant at a given time
point ("How many people are using an antidepressant today?"), while incidence
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provides the number of new starters of antidepressants during a specific time frame
("How many persons started on antidepressant last month?").
For the analysis, prescriptions of antidepressants as selected from ATC-codes N06A
(antidepressants only) and N06CA (combination of antidepressants with
neuroleptics) were used. To calculate the extent of prescribing, the database
covering 1994 and 1995 was used. Prescriptions from 1993 were used to
complement missing values in prescribed daily doses over 1994 and 1995 and to
help define the new starters of an antidepressant in the first half of 1994 (see under
incidence estimations).
Legend duration of use
For each prescription of an antidepressant in the database we created a time
window of probable use. This legend duration of use was calculated by dividing the
number of units dispensed by the number of units prescribed per day. This was
multiplied by 1.1 in order to take into account that patients often get their
prescriptions some days before they actually start the new package and to
compensate for some extent of non-compliance (24). In the event that information
regarding the prescribed dose was not available (9.3% of all antidepressant
prescriptions), it was obtained from the closest preceding prescription for the same
patient (3.9%) and if this was not successful (5.4%), the average prescribed dose for
that trade product in the database was used.
Prevalence estimation
The prevalence of antidepressant use was determined for 1994 and 1995 by
counting the number of patients having a prescription with a legend duration of use
including the third of October in each year and dividing these numbers by the
number of insured patients per age group in the respective year. The third of
October was chosen because this day falls within a time period during which most
people are presumed to not be on vacation. Advanced prescribing as a result of
vacations spent abroad is therefore less likely. In order to validate this date, the
analysis program was also run for several other random dates and the results were
similar.
Incidence estimation
Besides the prevalence rates, the incidence rates of new starters of antidepressants
were estimated over 1994 and 1995. A patient was defined as a new starter when he
or she started an antidepressant during this period and there was no valid
prescription for an AD in the half-year prior to this starting date. A patient is
counted as an incident user every time (s)he starts using an antidepressant after an
interval of more than a half year, as calculated above. (e.g. a prescription issued on
March 1st with tablets for 60 days, would be valid until March 1st plus 66 days:
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May 6th. Therefore, the first prescription that would classify this patient as an
incident user would be after May 6th plus 180 days: after Nov. 2nd). Increasing the
180 day-interval did not change results dramatically nor did changing the factor 1.1.
The ratio of prevalences and the ratio of incidences with their 95% confidence
intervals of highly AAD versus less AAD were calculated. 
RESULTS
The average number of persons insured at the health insurance company OZ during
1994 and 1995 was 236,207. Of the total population, 54% was female. Age
distribution was 23%, 38%, 22% and 18% for men and 19%, 35%, 25% and 21%
for women for the age groups under 20, 20-39, 40-59 and over 59 respectively. As
only the lower income brackets are subject to compulsory insuring by the national
health insurance system, the number of females is higher than the number of males
in the older ages groups because women more often work part-time or receive
welfare. The patients were registered with 160 general practitioners.
The total number of prescription records was 1,907,931 in 1993, 1,768,310 in 1994
(a substantial decrease because homeopathic and phytotherapeutic compounds were
no longer reimbursable) and 1,852,660 in 1995 which comprised approximately
92% of the number of pharmacy records originally reimbursed by the pharmacies.
The 8% of records that were discarded consisted mainly of extemporaneous
products (pharmacy made products; mainly dermatological ointments).
The total number of antidepressant prescriptions used for analysis were 34,776 for
1993, 39,637 for 1994 and 46,962 for 1995. The size of the insured population did
not change substantially during those years. The number of patients receiving
highly AAD in 1995 increased by 6% compared to 1994 (1636 highly AAD users in
1994, 1730 highly AAD users in 1995) while the increase for less AAD was 37%
(1489 in 1994, 2034 users in 1995) (Table 1). Amitryptiline was the most frequently
prescribed highly AAD; paroxetine was the most common less AAD. The absence
of exposure of patients to the combination preparation of amitriptyline and
neuroleptics in 1995 is due to the withdrawal of these products from the market in
1994. Sertraline, on the other hand, was introduced on the market in 1995, which is
reflected in Table 1.
The prevalence of patients treated with an antidepressant in 1994 increased from
0.54% for the age group 20-29 to 2.75% for the age group >69. The same pattern
was observed over 1995; however, these prevalences were on average 30% higher
(Table 2). Incidence rates over 1994 and 1995 demonstrated a similar pattern to the
prevalence data. Stratified for age, it appeared that less AAD were prescribed
preferentially for younger patients while highly anticholinergic compounds were
mainly prescribed for older patients in 1994 and in 1995 (Figures 1a and 1b). 
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Table 1: number of patients with a legimate prescription for the various highly anticholinergic antidepressants and less
anticholinergic antidepressants on the third of October in 1994 and 1995
The ratio of prevalences of highly AAD versus less AAD in 1994 increased steadily
with age from 0.54 in the age group of 20-29 to 1.73 in the group 69 years and older
(Table 3). In 1995 these age-specific prevalence ratios were all lower than in 1994.
However, the decrease was higher in the younger age groups (Table 3). The
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incidence rates and their ratios demonstrated a similar pattern to the prevalence
and prevalence ratios in 1994 and 1995 (Figures 1c and 1d , Table 2 and 3).
Interestingly, again the decrease in incidence rate ratios (IRRs) between 1994 and
1995 was more pronounced in the younger age groups than in the older. This
indicates that the elderly age groups were more likely to receive a highly AAD than
the younger ones, not only for repeat prescriptions, but also for new starters.
Moreover comparing 1994 and 1995 the portion of highly AAD decreased more for
the younger incident users than for the elderly. Separate analysis of females and
males demonstrated that the above described differences were found in both sexes.
Table 2: prevalence and incidence rates of antidepressant use for different age categories
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Figure 1b
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Figure 1d
DISCUSSION
These data indicate that elderly patients in the Netherlands are more likely to be
prescribed highly AAD than less AAD, whereas for younger patients the opposite
was true. Compared to 1994, the increased prescribing of less AAD in 1995 was
mainly observed in younger age groups.
Prior to interpretation of the results several points need to be discussed. In our data
we had no information as to indication. This information gap does not allow us to
accurately assess the alternatives for this fraction of anticholinergic exposure in the
elderly, but there are alternatives for each indication. In a recent survey among 142
patients using antidepressants, 75% were prescribed for depression, 19% for anxiety
disorders, 11% for sleeping disturbances, and 8% for neurologic pain (25). We think,
however, that despite the lack of clarity about the indication of antidepressant use,
suboptimal prescribing seems to be identified. Beers et al. (12) and Salzman (15)
recommend against prescribing any highly anticholinergic agents for the elderly.
Pharmacy data as used for the present study are very well validated in the
Netherlands (24) and allow reliable evaluation of medication prescribed to
individual patients. An important problem in collecting pharmacy records directly
from pharmacies is that when patients visit more than one pharmacy, medication
histories on a patient level may not be complete. By using data from an insurance
company, however, the medication histories are likely to be complete as all
prescriptions will be sent to the company the patient is insured at for
reimbursement purposes. It might be questioned whether our results are also
representative for the higher socio-economic classes which are not covered by the
national health insurance system. However, as there are no reimbursement
limitations for antidepressants in both the national health insurance system and
the private insurance companies, differences between socio-economic classes are
not expected.
An important strength of the present study is that we used prevalence and
incidence of drug prescribing to measure prescribing practices for antidepressants in
the population. Most drug utilization studies use the number of prescriptions or
‘Defined Daily Doses’ (DDDs) prescribed in a population. The DDDs of drugs are
defined by the WHO with the aim of representing the average dose of a drug per day
when prescribed for its primary indication. The latter parameters give information
on the extent of prescribing in populations and allow a comparison between the
prescribing of different drugs in one class. These parameters, however, do not
provide insight into the fraction of people that are exposed to specific drugs or drug
classes nor do they give insight into the number of new drug starters.
The prevalence data give insight into the percentage of the population exposed to
each antidepressant, but do not reflect very well the drug preferences of prescribers
at that moment. Although a doctor may have a preference for certain compounds,
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she may still prescribe less-preferred compounds because of unwillingness to
change medication a patient is satisfied with. Incidence measures, representing new
episodes of drug use, give more insight into the drug preferences of doctors during
the period the data are collected. Therefore, incidence is a sensitive measure to
evaluate the influence of an intervention.
In our study we observed that the fraction of the population that was exposed to
highly AAD versus the fraction that was exposed to less AAD in 1994
demonstrated a decrease in 1995. At least part of this change was caused by an
increase in the preference to prescribe less anticholinergic compounds (especially
SSRIs) from 1994 to 1995 as shown by the incidence data. Also, this change may
have been induced by an increased switching of highly AAD prescribing to less
AAD prescribing.
Our study demonstrated that there was an increase of 20% in the number of
patients that were prescribed antidepressants when 1995 was compared with 1994.
This increase was mainly caused by an increase in the prescribing of less AAD
(37% increase compared to 6% increase in the highly AAD), mainly by the
prescribing of SSRIs. Although the tolerability of the SSRIs appears to be superior to
that of the older generation antidepressants (21), there is still discussion about the
benefit/risk ratios, partly in relation to their costs. In the Netherlands this
uncertainty is expressed in the different preference statements for antidepressants
in two recent consensus reports (16,17). It may be clear that the benefit/risk ratio of
the SSRIs increases in the elderly. It is interesting to see that in times of
controversial guidelines, those who, in theory could have benefited most from a
new development (the elderly) have not. Possible explanations are that these side
effects are not so striking in daily practice or that the elderly do not complain of
these side effects. Furthermore some people may experience side effects and stop
taking their medication without informing their physician. Further research is
needed to establish the side effect burden of different antidepressants. 
This study indicates, using HIC data to obtain prevalence and incidence figures of
antidepressant prescribing, that physicians do not refrain from prescribing highly
anticholinergic antidepressants to older patients despite their potential adverse drug
reactions in this age group and the availability of safer alternatives. 
We used these findings as a starting point for an intervention on antidepressant
prescribing in the elderly. 
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HOOFDSTUK 4 
Bijwerkingen van verschillende soorten antidepressiva bij ambulante ouderen
Wat vonden de ouderen er zelf van?
In dit hoofdstuk wordt beschreven wat de resultaten waren van ons onderzoek naar
de aard en de ernst van klachten die ouderen hebben bij het gebruik van
antidepressiva. We wilden vooral de verschillen in kaart brengen tussen de
bijwerkingen die optreden bij het gebruik van minder anticholinerge en sterk
anticholinerge middelen. Welke klachten meldden de patiënten in de dagelijkse
praktijk zelf?
We hebben dit onderzocht met behulp van een vragenlijst. Alle mensen boven de 60
jaar in de onderzoeksgroep die in 1995 een antidepressivum slikten, ontvingen een
vragenlijst; in totaal ging het om 2.359 patiënten. We vroegen in deze enquête naar
hun geneesmiddelengebruik en de klachten die zij daarvan ondervonden. In een
bijgevoegde uitgebreide lijst konden zij aankruisen waar zij last van hadden. 945
mensen retourneerden een ingevulde vragenlijst, waarvan er 876 geschikt waren
voor analyse.
Bij de analyse bleek dat een grote groep mensen gestopt was met het slikken van
antidepressiva. In eerste instantie vonden we dat erg teleurstellend. Tot we ons
realiseerden dat ‘de gestopte groep’ juist een goede controlegroep was. We hebben de
vragenlijsten in drieën gedeeld: één groep van gestopte gebruikers, één groep van
gebruikers van sterk anticholinerge antidepressiva, en een groep die minder
anticholinerge antidepressiva slikte.
Tot onze verbazing meldden gebruikers van antidepressiva niet meer klachten dan
niet-gebruikers. Ook meldden de mensen die een sterk anticholinerg geneesmiddel
gebruikten niet meer bijwerkingen dan zij die een minder anticholinerg middel
slikten. Doordat de klacht ‘een droge mond’ wel significant meer voorkwam bij de
groep gebruikers van sterk anticholinerge middelen, wisten we dat we wél goed aan
het meten waren; aan het onderzoek lag het niet. 
Hoe kan dit kleine verschil in klachten verklaard worden? Wellicht houden artsen
bij het voorschrijven van medicatie rekening met al bestaande klachten,
bijvoorbeeld obstipatie. We hadden bijvoorbeeld verwacht dat veel mensen die sterk
anticholinerge middelen slikken verstopping zouden noemen als klacht. Er was
echter geen sprake van een significant verschil.
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CONCLUSIE
Over het geheel genomen bleek uit ons onderzoek niet dat gebruikers van sterk
anticholinerge middelen meer klachten hebben dan gebruikers van minder
anticholinerge antidepressiva. Dit kan mogelijk verklaard worden doordat artsen
rekening houden met de specifieke bijwerkingen van de sterk anticholinerge
middelen.
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Adverse events in community-dwelling
elderly using highly-anticholinergic versus
less-anticholinergic antidepressants 
submitted for publication
Martine E.C. van Eijk, Jerry Avorn, Arijan Porsius,
Anthonius de Boer
"Rabbit’s clever," said Pooh thoughtfully. 
"Yes," said Piglet, "Rabbit’s clever." 
"And he has Brain." 
"Yes," said Piglet, "Rabbit has Brain." 
There was a long silence. 
"I suppose," said Pooh, "that that’s why he never understands
anything." 
A.A. Milne, The house at the Pooh corner, 1928. 
Chapter: A very grand thing, page 127. 
Abstract
Objective: To compare the prevalence of adverse events in users
of highly-anticholinergic versus less anticholinergic
antidepressants, in a typical population of elderly patients.
Design: Cross-sectional survey with questionnaires
Setting: South Holland Islands, 1995
Participants: Elderly patients (age between 60-95 years) who used
antidepressants in 1995 were identified using a health insurance
prescription database. 
Main outcome measure: Prevalence of reported adverse events,
expressed as odds ratios (and 95% confidence intervals) in elderly
using two categories of antidepressants as well as former users. 
Results: Of 867 respondents, 429 patients had stopped
antidepressant use at the time of the questionnaire. These
patients served as controls. Adverse events in users of highly-
anticholinergic antidepressants (n=268) varied from 5%
(difficulties with urination) to 51% (dry mouth). Users of less
anticholinergic antidepressants (n=170) had a different pattern of
adverse events, but about the same number of symptoms; rates
ranged from 3% (constipation) to 40% (difficulty falling asleep).
The frequency of symptoms reported by both groups were similar
to those seen in former users. Evaluation of the association of
anticholinergic adverse events in the two groups of
antidepressant users compared with former users revealed two
significant associations: dry mouth and incontinence occurred
more often in users of highly anticholinergic antidepressants
than in former users (odds ratios 1.8 (1.3-2.5) and 1.5 (1.0-2.2),
respectively). Evaluation of mood and quality of life
demonstrated no differences between both groups of users, in
contrast to the control group, which scored better for both.
Conclusions: The number of adverse events reported by
community-dwelling elderly using highly-anticholinergic
antidepressants as well as less-anticholinergic antidepressants
are both high, and similar to complaints mentioned by former
users of antidepressants; only dry mouth and incontinence were
reported significantly more often in users of highly
anticholinergic antidepressants. Confounding by
contraindication may explain these findings. 
Keywords: antidepressants, side effects, adverse events,
anticholinergic, questionnaire, community dwelling elderly
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INTRODUCTION
The advantages and disadvantages of the various types of antidepressants are a
source of continuing debate. Most of this is focused on the costs and the benefit-
risk ratio of tricyclic antidepressants (TCA) and selective serotonin re-uptake
inhibitor (SSRI) agents (1-4). The overall impression from trials is that the efficacy
of both groups of antidepressants is more or less equal, but there is widespread
belief that SSRI seem to have fewer side effects. The anticholinergic side effects of
older TCAs may play an important role in the differences between both groups of
antidepressants. Much research has emphasized the side effects of highly-
anticholinergic drugs in this class, and the vulnerability of the elderly to these
adverse events. Some authors even advise against prescribing any highly
anticholinergic compounds to the elderly if alternatives are possible. (5-7). In a
former study of ours we have shown that the elderly still use many highly-
anticholinergic antidepressants (8), despite the availability of less-anticholinergic
compounds. As most knowledge of adverse events is generated in trials, in which
the elderly are often underrepresented (9-12), we wanted to assess the prevalence of
antidepressant adverse events among elderly in daily practice. The aim of this study
was to describe the prevalence of adverse events in community-dwelling elderly
using highly-anticholinergic antidepressants and less-anticholinergic
antidepressants. 
METHODS
Study Design
The relationship between antidepressant use and adverse events in an ambulatory
setting was evaluated with a cross-sectional study design. We compared elderly
using highly-anticholinergic antidepressants and those using less-anticholinergic
antidepressants with a control group of former users of antidepressants.
Population
The study population consisted of antidepressant users between 60 and 95 years old
who were insured at health insurance company "OZ zorgverzekeringen" (Mutual
Care health insurance) in the Netherlands. The insured population consisted of
98% of those in the South Holland Islands area that were compulsorily insured by
the national health insurance system. This so-called "Sickness Fund" insures
patients in the lower income brackets, comprising approximately 65% of the
population in the Netherlands. Of the approximately 240,000 persons insured at
"OZ zorgverzekeringen" in this area, approximately 56,150 persons were between
60 and 95 years old. Users were defined by use of at least one antidepressant (table
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1) reimbursed in 1995. We identified 2,359 different users of antidepressants in the
prescription databases. 
Table 1: Drug Classification
Prescription Data
The drug reimbursement database used for this study was obtained from the health
insurance company "OZ zorgverzekeringen" and consisted of complete drug
dispensing histories of the insured population from 1 July 1993 to 31 December
1996. These drug-dispensing records were collected in pharmacies and sent to the
health insurance company on either diskette or magnetic tape for reimbursement
purposes. The data did not include the person's name, but included the family
insurance number, the date of birth and sex. Unique combinations of family
insurance numbers, birthday and sex identified individual users. The drug-related
information consisted of a unique product code, the prescriber, the dispensing date,
the number of units dispensed and the prescribed daily dose. Linking the product
code to other databases gives access to information on ATC, total DDDs (defined
daily doses) in the package, brand name, dispensing unit and costs (13).
Drug Classification
The antidepressants were classified with regard to their in vitro and in vivo
anticholinergic effects, based on standard literature and publications found by a
literature review using Medline (14-19). In addition, the evaluations as published in
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the 'Farmacotherapeutisch Kompas' (a Dutch equivalent of the British National
Formulary) were used.
The following agents, which are marketed in the Netherlands, were classified as
highly-anticholinergic: amitriptyline, clomipramine, doxepin, imipramine,
maprotiline and trimipramine (8). All other agents belonging to the group of
antidepressants according to the ATC classification were classified as causing fewer
anticholinergic effects and were considered less-anticholinergic agents. (table 1)
Questionnaire
The questionnaire sent to patients comprised questions on basic characteristics
(sex, age, marital state, household, religion, education, occupation, smoking, coffee
and alcohol use), current medication use, symptoms (including a list of known
antidepressant side effects and complaints), health care utilization in the former
year, the Geriatric Depression Scale (GDS) and the COOP-WONCA Health charts
(20-22). The questionnaires were sent out in March 1996. 
Procedures
After identifying the users of antidepressants in 1995 from the prescription
reimbursement databases, their codes were further processed at the health
insurance company. Address labels were made at "OZ zorgverzekeringen" and
questionnaires were sent from there. A stamped return envelope was enclosed.
When questionnaires were returned they were coded and the consent form (the
only sheet including the respondent’s name) was removed and filed at a different
location.
Exposure Definition
Exposure assessment was done using the answers in the returned questionnaires.
To examine adverse events experienced by elderly using anticholinergic
antidepressants we divided users into two groups: those using highly
anticholinergic antidepressants and those using an antidepressant not having a
strong anticholinergic component (see drug classification and table 1). Respondents
who did not report antidepressant use were used as a control group of former
antidepressant users, as selection criterion for the questionnaire had been the
reimbursement of at least one antidepressant prescription in the preceding year.
Statistical Analyses
Data were processed using FoxPro ® and SPSS ® (for Windows, release 6.1.3).
Frequencies of adverse events were calculated in each of the three patient groups.
Odds ratios and their 95% confidence intervals were calculated to estimate the risk
of specific adverse events in users of highly-anticholinergic antidepressants and
less-anticholinergic antidepressants, using a logistic model. All associations with
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adverse events were assessed in separate models. For the exposure variable, users
were categorized as highly-anticholinergic antidepressant users, less-anticholinergic
antidepressant users and controls (subjects who did not report antidepressant use).
Crude odds ratios were obtained, only coding for antidepressant use. Adjustment for
potential confounders was accomplished by entering other prognostic factors (sex,
age, mood and pain) into the model. All variables were entered into the model after
categorization (with age treated as a continuous variable). 
RESULTS
We sent 2,359 questionnaires, of which 945 were returned. Eighteen responses had
too many missing values to evaluate, and another sixty were answered by a family
member other than the patient addressed. 867 (37% of 2,359) questionnaires were
used for the current report. There were no material differences between the
response and the non-response population concerning sex and age distribution and
antidepressant use (average age 71.8 vs. 73.2 years old; women: 74.2% vs. 74.7%).
Population characteristics are presented in table 2. Of these 867, 429 respondents
reported no antidepressant use. Highly anticholinergic antidepressant use was
reported by 268 respondents. Of the 173 respondents reporting use of less-
anticholinergic antidepressants, three also reported use of a highly anticholinergic
antidepressant. These three were allocated to the highly-anticholinergic
antidepressant users. The other 170 respondents were analyzed as less-
anticholinergic antidepressant users.
Table 2 Population Characteristics (baseline)
Tables 3a and 3b list the reported adverse events. When comparing crude rates,
elderly using anticholinergic antidepressants were likeliest to report the known
side effects of these drugs (dry mouth, constipation, dyspepsia and incontinence). 
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By contrast, while users of less-anticholinergic antidepressants had lower
frequencies of these adverse events, they complained more of nausea, dizziness,
impaired concentration and dripping. The crude rate of occurrence of adverse
events ranged from 3% (stool freq.< 2/week) to 40% (difficulty falling asleep) for
less-anticholinergic antidepressants and from 5% (various difficulties urinating) to
51% (dry mouth) for highly anticholinergic antidepressants (Table 3a and 3b).
Difficulty urinating as well as constipation were each mentioned by 4% of the non-
users. Among controls, 42% mentioned difficulty falling asleep. 
The crude rate differences of complaints between the two groups of drugs ranged
from 12% more dry mouth with highly-anticholinergic antidepressants to 8% more
nausea with less-anticholinergic antidepressants. Table 3a and table 3b also present
the estimated ORs of all adverse events. Significant increased risks were found for
dry mouth and incontinence for users of highly-anticholinergic antidepressants.
However, users of less-anticholinergic antidepressants were significantly more
likely to report emotional numbness and an increased reaction time. Adjusted ORs
did not differ considerably from the unadjusted ORs and are not presented here. 
Table 3c lists the effectiveness of drug therapy. Our results demonstrate that users
of both classes of antidepressants show similar scores on the GDS depression scale
and perception of overall health lately. Whereas the control group showed better
scores for both mood and overall health lately.
DISCUSSION
In this population-based survey of typical elderly patients taking antidepressants,
we found a different pattern of adverse events in users of highly-anticholinergic
antidepressants when compared to users of less-anticholinergic antidepressants.
However, the number of adverse events reported was similar in both groups, and
similar to the number reported by former users of antidepressants. Clinical trials
tend to include selected patients under clearly defined circumstances. As a result,
their findings cannot always be extrapolated to daily practice. The effectiveness of a
therapy and its adverse events may be different when a therapy is applied to
another population under different circumstances. This is especially true for the
elderly. (12). 
In addition to trials, observational studies can provide information about the
effectiveness and unintended effects of drugs in specific populations in daily
practice. Adverse events may have an effect on compliance and can be a cause of
additional health care costs (23) (24). Much observational research involving the
elderly is done in nursing homes and similar settings. The majority of these studies
focus on one adverse event or lack controls (7,15,25-28). Our study compared a wide
range of adverse events reported by a population of typical ambulatory elderly using
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antidepressants, including a control group of former users of antidepressants.
Former users of antidepressants were expected to be more comparable with current
users than a control group of which antidepressant use is unknown. A problem
might be that non-users in our study in reality are non-reporters of current use.
However, comparison with pharmacy records showed that most of them indeed had
stopped using antidepressants. Antidepressants are used for several indications and
the distribution of indications will certainly not be equal in the former user, less-
anticholinergic antidepressant and highly-anticholinergic antidepressant user
groups. Although our data show an equal distribution of population characteristics,
mood scores and recent overall health, confounding by indication across the
treatment categories cannot be excluded with certainty.
Confounding by contra-indication may explain our finding that the anticholinergic
adverse events were not dramatically higher in the highly-anticholinergic
antidepressant users compared to the less-anticholinergic antidepressant users. For
instance, when a patient has constipation or urinary problems, doctors may
discontinue the offending drug and prescribe less-anticholinergic antidepressants.
Thus there may be more patients already suffering anticholinergic-like complaints
in the less-anticholinergic antidepressant user group. We do not have information
on the start of the complaints in relation to the start of the drug. Thus, although
there are no indications that the adverse event burden for users of highly-
anticholinergic antidepressants is substantially higher, this could be explained by
confounding by contraindication. 
Another explanation of our findings can be that because patients with adverse
events had stopped their antidepressants, resolving the adverse events. Alongside
that, many of the adverse events reported may not have been caused by the
antidepressants.
The frequency of adverse events does not reflect how patients experience the
seriousness of these events. This could be assessed using quality of life scales and
needs further research. Our results show no difference in effectiveness of either
group of antidepressants on depression or overall quality of life.
Lack of significance can be due to small sample size. However, this study
comprises a large population compared to most previous studies of typical elderly.
Response bias could have caused under or overestimation of adverse events.
Although in theory the elderly are prone to suffer anticholinergic adverse reactions
and should therefore not be prescribed highly-anticholinergic antidepressants, this
could not be confirmed in our research population. Community-dwelling elderly
using highly-anticholinergic antidepressants did not report more adverse events
than elderly using less-anticholinergic antidepressants. Moreover, the number of
adverse events in the antidepressant users was comparable with that seen in former
users of antidepressants. 
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Conclusion
The elderly patients we studied reported a substantial number of adverse events
during the use of both highly-anticholinergic antidepressants and less-
anticholinergic antidepressants. These differed in nature, but not in frequency
between the older and newer drug classes. In addition the number of symptoms
reported by current antidepressant users of both types was similar to that seen in
former users of antidepressants. The small differences in occurrence of
anticholinergic adverse events in both antidepressant groups may be caused at least
in part by confounding by contraindication, as would be expected if prescribers
were aware of drug-specific adverse event risks and avoided or discontinued use of
problematic drugs in patients with such symptoms.
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Een vergelijking van verschillende depressiescorelijsten bij ambulante ouderen
Een lastige diagnose
Depressie bij ouderen is een belangrijk probleem. Een depressie leidt tot veel verlies
van de kwaliteit van leven voor de patiënt. Daarnaast doen depressieve ouderen
doorgaans een groot beroep op de gezondheidszorg; er is dus waarschijnlijk veel geld
mee gemoeid.
Depressie is moeilijk te diagnosticeren. Er bestaan verschillende scoringslijsten om
depressiviteit te meten. Wij hebben hiervan een aantal met elkaar vergeleken in één
populatie van ambulante (min of meer zelfstandig wonende) ouderen. Het is
belangrijk om een goede diagnose van depressie te kunnen stellen. Wanneer er een
behandelprotocol voor depressiviteit bij ouderen bestaat, is er uiteraard ook een
indicatie nodig. Want: wanneer valt iemand onder dat protocol? Daarom was het
voor de hand liggend om in deze studie ook de uitkomsten van verschillende
scoringslijsten met elkaar te vergelijken.
De enquête die we rondstuurden aan ouderen die antidepressiva gebruikten, bevatte
vier verschillende scoringslijsten om (de mate van) depressiviteit te meten. Dus op
vier verschillende manieren werd de mensen gevraagd informatie te geven over hun
gemoedsgesteldheid en over hun – doorgaans aan depressie gerelateerde –
lichamelijke klachten. Dit hoofdstuk beschrijft de mate van depressiviteit die
mensen scoren bij de verschillende lijsten. De depressiescores die deze lijsten
opleverden, hebben we met elkaar vergeleken. Behalve dat er sprake was van een
behoorlijke overlap, bleek bij analyse ook dat waar de ene lijst een ernstige
depressiviteit aangeeft bij maar liefst 60% van de ondervraagden, de andere slechts
bij 24% van de ondervraagden tot die conclusie komt.
CONCLUSIE
We denken dat het belangrijk is dat hulpverleners weten dat deze lijsten grote
verschillen in uitkomst kunnen opleveren, en dat depressie bij ouderen moeilijk te
diagnosticeren is.
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Comparison of various depression scales in a
group of ambulatory elderly 
Nelly Cisneros-Gonzalez, Martine E.C. van Eijk, 
Arijan Porsius, Anthonius de Boer
submitted for publication
"Tigger is all right, really," said Piglet lazily.
"Of course he is," said Christopher Robin. 
"Everybody is really," said Pooh. "That’s what I think," said
Pooh. "But I don’t suppose I’m right," he said. 
"Of course you are," said Christopher Robin. 
A.A. Milne, The house at the Pooh corner, 1928. 
Chapter: Eeyore joins the game, page 105.
Abstract
Background: Depression in the elderly is a major public
health problem, resulting in a loss of quality of life and
high demands on health services. One problem is that
depression is underdiagnosed and undertreated. There
are several validated scales available to score depression.
However, these scales have not been compared with
each other in the same population.
Methods: we invited a group of 2,359 elderly patients (60
years of age and older), who had used an antidepressant
in the year prior to our investigation, to participate in a
questionnaire. The patients were identified by a
pharmacy record database of a health insurance
company in the Netherlands. The questionnaire
contained questions about general patient
characteristics, the Geriatric Depression Scale (GDS),
the VROPSOM list, part of the COOP/WONCA
questionnaire. Correlations between the different rating
scales were calculated by Pearson’s correlation
coefficient.
Results: 945 questionnaires (40%) were returned of
which 867 (37%) could be used for statistical analyses.
Correlations between different rating scales varied
between 0.43 and 0.55 (all estimates p<0.0001). There
were substantial differences in the percentages of
patients with signs of depression when different scales
were compared: GDS 55%, VROPSOM 24%,
COOP/WONCA 81% and the question "Do you feel
sad?" 35%.
Conclusion: Our study shows that health care workers
who use depression rating scales should be aware of
substantial differences in their potential to detect signs
of depression.
Keywords: depression rating scales, elderly, primary
health care, healthy insurance company
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INTRODUCTION 
The prevalence of depression in elderly people varies strongly in different surveys
but is often reported to be 12-15% (1,2). As is the case in many other countries, in
the Netherlands depression is a public health problem among the elderly. The
prevalence of major depression in primary care is reported to be 8%, and of minor
depression 17% (3).
One problem in primary care is that not all cases of depression are recognized;
several studies have shown substantial underdiagnosis and undertreatment of
depression in the elderly (4). There are several factors that may be an obstacle to
detecting depression in the elderly. First, some general practitioners may possess an
inadequate diagnostic capacity (5,6). This might be caused by a reluctance to
discuss feelings, a lack of knowledge of the prevalence of depression in the elderly
and confusion about the role and use of self-report questionnaires to detect
depression. Second, comorbidity might lead to misinterpretation of symptoms of
depression (1).
The use of rating scales for depression in daily practice is potentially helpful to
detect depression when such a diagnosis is suspected. Although rating scales are
sometimes used, this is still not common practice (7).
Validated depression scales are the Geriatric Depression Scale (GDS) (4), the
Depression Adjective Check Lists (DACL = VROPSOM lists) (8) and part of the
Dartmouth COOP Functional Assessment Charts WONCA (COOP/WONCA) (the
emotional condition component) (9). Although these rating scales are all validated,
not necessarily in the elderly, they have not been compared directly with each
other in a population of elderly subjects. As each scale uses different criteria to
detect depression, differences in the scoring of depression might occur.
The aim of our study was to perform a direct comparison of different rating scales
for depression in a group of elderly people.
MATERIALS AND METHODS
The data used for the present study were part of a larger project in which
intervention strategies were evaluated for their potential to influence the
prescribing of antidepressants in primary care (10). The project was performed in a
research area that is part of the area of the health insurance Company ‘OZ
zorgverzekeringen’ in the Southwest Netherlands. Approximately 240,000 people
(60% of the population in the research area) were insured through ‘OZ
zorgverzekeringen’ of which 50,000 were 60 years of age or older.
Prior to this intervention, a questionnaire was sent in 1996 to all elderly people (60-
95 years of age) in the research area who had used an antidepressant in 1995.
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Patients were identified using the reimbursement databases that pharmacists send
to the health insurance company. The questionnaire contained questions about
general patient characteristics (including morbidity), the GDS (30 yes/no questions)
(11) the VROPSOM list (34 yes/no items) (8), and the COOP/WONCA, which
includes five pictorial choice charts assessing functioning in emotional condition
areas (9). 
Furthermore, the closed-ended question "Do you feel sad?" (Yes /no answer) (4) was
included in the questionnaire. We used Dutch translations of the different rating
scales. The questionnaires were sent to patients with postage paid return envelopes.
Analysis
After applying internationally accepted cut-off values to diagnose depression for the
various rating scales (GDS: no depression <11 questions yes, mild depression 12-20
questions yes and severe depression >20 questions yes (11); VROPSOM: no
depression >=7 items yes and depression <=7 items yes (8)), the scales were
compared to each other by Pearson’s correlation coefficient (SPSS) and by
comparing the prevalence of depression as scored by the different scales.
RESULTS
In the pharmacy records of the health insurance company, 2,359 elderly patients
who had used an antidepressant in 1996 were identified. A total of 945
questionnaires (40%) were returned and of these, 867 (37%) could be used for
statistical analysis. Seventy-eight questionnaires were excluded because of errors in
completion of the questionnaire.
The population in this study consisted of 68% women and 32% men, with a mean
age of 71 years (standard deviation 7.4). All respondents were using antidepressants
at the time of completion of the questionnaire. The most frequently self-reported
medical problems are presented in Table 1.
The Pearson’s correlation of the different rating scales and the question "Do you
feel sad" varied between 0.43 and 0.55 (all correlation estimates p<0.0001) (Table 2).
Although there was a reasonable correlation between rating scales, the prevalence
of depression as scored by the different scales showed substantial differences.
According to GDS, VROPSOM, COOP/WONCA and the closed-ended question,
slight to severe depression was present in 55%, 24%, 81% and 35% of respondents,
respectively. In 123 patients (14% of the total group) all rating scales scored positive
for depression. Sixteen percent (141 respondents) rated as not depressed across all
rating scales and the question "Do you feel sad?"
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Table 1: General Characteristics of Patients
Table 2: Pearson’s Correlation of COOP/WONCA, GDS and VROPSOM rating scales and the question "Do you feel sad?"
Table 3: Outcome of four depression rating scales in a group of 867 patients
DISCUSSION
Although there is a reasonable correlation between the different rating scales for
depression, our study demonstrated that there are substantial differences in the
number of patients detected as depressed when applying the different scales in the
same patient group. As we had no ‘gold standard’ (psychiatric interview) in our
study, it is not possible to conclude which rating scale performed best. There may
be both overdiagnoses and underdiagnoses (false positives and false negatives) for
the different scales.
The prevalence of depression that was estimated in our study cannot be
extrapolated to the entire population of elderly. Our study used a group of patients
that were treated with an antidepressant the year prior to our investigation.
Although antidepressants are used for other indications as well, the prevalence was
expected to be high in our population. This was confirmed by our data. We found
prevalence of signs of depression varying from 24% to 81%. Although our group
was not representative for the elderly in the Netherlands, this does not jeopardize
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our comparison of the different rating scales. In fact, it is helpful that there is a
large variation in the level of depression in our patient group, increasing the power
of our statistical comparisons. We also do not expect that the low response rate has
influenced our results since we have no reason to assume that the comparison of
the different rating scales in the non-responders will be different.
Early diagnosis and treatment of depression in the elderly remains challenging to
the clinician, but ultimately provides opportunities to reduce suffering and increase
the quality of life, to prevent suicide, to restore optimal levels of functioning and
independence, and to decrease the societal costs of health care (1). 
Although we cannot say which rating scale performed best, one important
conclusion, which can be drawn, is that the chance of a patient to be diagnosed as
depressed depends heavily on the rating scale being used. These results stress the
importance for further research into the value of different depression rating scales
in the elderly. 
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Kenmerken van FTO-groepen: betekenis voor stratificatie in een
gerandomiseerde interventie
FTO-groepen
In Nederland werken huisartsen en apothekers in groepen samen om kennis uit te
wisselen, te discussiëren en afspraken te maken over de kwaliteit van
farmacotherapie. Deze zogenaamde farmaco-therapie-overleggroepen (FTO’s)
bestaan al geruime tijd.
De Nederlandse aanpak is uniek in de wereld, en staat model voor soortgelijke
initiatieven in andere landen. Deze werkvorm is namelijk een heel goede manier
gebleken om in de eerste lijn samen te werken. Artsen die deel uitmaken van een
FTO-groep blijken rationeler en goedkoper voor te schrijven. 
Omdat FTO-groepen zo belangrijk zijn, wilden wij deze groepen ook betrekken bij
onze interventie. We wisten dat deze groepen van grote invloed zijn op de kwaliteit
van voorschrijven. Daarom vonden we het belangrijk om vóór de interventie al te
kijken hoe de FTO-groepen in de onderzoeksregio samenwerkten, èn om ervoor te
zorgen dat de groepen die intensief samenwerkten gelijkelijk verdeeld zouden
worden over de interventiearmen (de drie onderzoeksgroepen, zie hoofdstuk 7).
Veel Verschillen
Dit hoofdstuk beschrijft de resultaten van telefonische interviews die we hebben
gehouden onder de FTO-groepen in de onderzoeksregio. In deze interviews vroegen
we naar allerlei kenmerken van de FTO-groepen, zoals de organisatiestructuur en
de doelstellingen. Maar ook welke voorbereiding er aan een FTO voorafgaat, welke
lesvormen er worden gebruikt en of er afspraken worden gemaakt. Hoe bindend zijn
deze? (zie appendix Questionnaire)
Uit de interviews bleek dat er sprake is van enorme verschillen (zie tabellen 1 tot
3). Sommige groepen werkten al lang samen, andere nog maar kort. Sommige
kwamen regelmatig bij elkaar, andere maar zeer incidenteel. Soms bestond de groep
uit niet meer dan vier artsen en een apotheker en soms wel uit zestien artsen en
vijf apothekers. Verder hanteerden de groepen zeer verschillende werkvormen. 
Criteria voor Randomisatie en Stratificatie
Om het effect van de interventie goed te kunnen meten moesten we FTO-groepen
met belangrijke kenmerken willekeurig (gerandomiseerd) en gelijkelijk
(gestratificeerd) verdelen over de interventiearmen. Daarom moesten we kiezen
welke kenmerken relevant zouden zijn voor een gewogen verdeling van de FTO-
groepen over deze interventiearmen. Allereerst vonden wij het van belang of de
groep werkte met een formularium. Een formularium is een ‘voorkeurslijst van
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geneesmiddelen’ die de arts hanteert, waarin omschreven staat welk geneesmiddel
in welke situatie de meeste voorkeur geniet. Het gebruik van een gezamenlijk
formularium is een teken dat de groep streeft naar het rationaliseren van het
voorschrijfbeleid. Verder vonden we het belangrijk of een groep ervaring had met
prescriptieterugkoppeling (overzichten van het eigen voorschrijfgedrag). Ten slotte
vonden we het relevant of een groep te kennen gaf naar consensus te streven, en
dus in principe ‘bindende’ afspraken wilde maken. 
CONCLUSIE
Na de interventiestudie en de analyse van resultaten konden we bevestigen dat
deze kenmerken inderdaad effect hadden op het effect van de interventie.
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Characteristics of Dutch peer review
groups: implications for stratification in a
randomized trial
submitted for publication
Martine E.C. van Eijk, Mieke Muris, Arsenio H.P. Paes,
Arijan Porsius, Jerry Avorn, Anthonius de Boer
"How would it be?" said Pooh slowly, "if, as soon as we’re out
of sight of this Pit, we try to find it again?" 
"What’s the good of that?" said Rabbit.
"Well," said Pooh, "we keep looking for Home and not finding
it, so I thought that if we looked for this Pit, we’d be sure not to
find it, which would be a Good Thing, because then we might
find something that we weren’t looking for, which might be just
what we were looking for, really."
A.A. Milne, The house at the Pooh corner, 1928. 
Chapter: Tigger is unbounced, page 121.
Abstract
Background: In experimental studies, stratification prior to
randomization is a well-known technique to prevent imbalance between
treatment groups in factors that may strongly influence prognosis or
treatment responsiveness. Although such stratification is often used in
trials in which patients are randomized, it is seldom performed when
groups are randomized. This study reports on the process of selection of
characteristics of peer review groups (PRGs; groups of primary care
physicians and community pharmacists) thought on theoretical ground
to be relevant for the responsiveness to an educational outreach program
aimed to change prescribing. After the outreach program was tested in a
controlled trial in which PRGs following stratification were randomized
over treatment arms, we evaluated whether the selected characteristics
indeed modified the effect of our intervention. 
Methods: Representatives of 61 PRGs in our research area were asked to
participate in a telephone interview. The interview consisted of
questions on organizational structure of the PRG, how meetings were
prepared and presented, and the level of binding agreements on
pharmacotherapy. Changes in prescribing within strata thought to be
relevant for the effect of our outreach program were evaluated by
estimation of incidence rate ratio's (Poisson regression)
Results: Forty representatives of PRGs (66%) participated in our study.
Based on responses and theoretical considerations we found the aim of
the group (information exchange (n=14) versus binding consensus on
pharmacotherapy (n=26)), the use of a formulary (22 PRGs did and 18
PRGs did not) and the use of feedback data (22 PRGs did and 18 PRGs
did not) most relevant to use for stratification. After evaluation of our
educational outreach program it appeared that the characteristics we had
selected strongly modified the effect of our program, on prescribing
behavior. While the overall effect was that prescribing was significantly
changed by our program this change was not observed when PRGs were
selected on the basis of working with binding consensus, not using
feedback and not using a formulary. 
Conclusion: Based on theoretical considerations and inventory of
characteristics of PRGs we were able to define factors to be used for a
stratified randomization of PRGs which in retrospect indeed strongly
modified the effect of an educational outreach program directed to
change prescribing. 
Keywords: stratification, randomization, peer review groups, educational
visits, rational drug use, continuing medical education
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INTRODUCTION
When organizing an experimental intervention in natural populations, stratification
prior to randomization offers an opportunity to prevent imbalance between
treatment groups in factors that may strongly influence prognosis or treatment
responsiveness. Control of such variability can lower the occurrence of type l errors
and improves power for small trials. While it is important to define stratification
factors that have a relevant effect on prognosis or treatment responsiveness, it is
also important to avoid creating too many strata (1). Most literature on
stratification strategies is based on interventions at an individual (e.g. patient) level.
Although educational interventions are often organized at a group level, there is
hardly any literature on the role of stratification of groups within a group approach
intervention (2). 
Recently we performed a three-arm randomized controlled trial to compare the
effect of individual educational visits and group visits versus no visits on the
prescribing of highly anticholinergic antidepressants in the elderly (3) As unit of
randomization we used peer review groups (PRG). In the Netherlands the
expression ‘peer review group‘ (PRG) is used for regular meetings of groups of
primary care physicians and pharmacists to discuss pharmacotherapy and improve
the quality of pharmacotherapy. This type of interdisciplinary groups are
increasingly popular in other countries as well (4). For our trial we performed a
stratified randomization of PRGs as we expected based on literature review that
certain characteristics of PRGs would modify the effect of our intervention on
prescribing. 
Characteristics of PRGs that support dissemination of knowledge have been
described by several authors (5-11). The qualities mentioned can be divided into
those concerning organizational structure, those on goals and consensus, and those
on preparation and presentation. 
This paper describes the process of how we selected characteristics of PRGs that
were used to perform the stratified randomization and reports whether these
characteristics indeed modified the effect of our intervention (changing of
prescribing behavior). 
METHODS
Study Design and Participants
We contacted representatives of all PRGs in the primary working area of the health
insurance company "OZ zorgverzekeringen" in the Southwest Netherlands (61 Peer
Review Groups, insured population approximately 600,000 persons). These
representatives were primary care physicians and pharmacists. Within two weeks
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after being sent a letter of introduction, these representatives were approached to
make an appointment for a structured telephone interview. The interviews were
completed by the same person (MM) in a period of four months. 
Questionnaire
The questionnaire contained questions about characteristics of the PRGs: the
organizational structure, attitudes towards achieving consensus, and the way topics
to discuss were prepared and presented (7,8).
Organizational Structure
Most literature on PRGs is based on the paradigm that highly structured
consultations will produce better results (5). A better structure facilitates problem-
solving collaboration and improves the results of the meeting (9). Structured
cooperation results in more cooperation between primary care physicians and other
first-line disciplines and leads to changes in drug therapy (12). The minimal
requirements of structural organization are generally considered to be: group size
between 5 and 15 professionals, frequency of gatherings between 5 to 10 per year,
duration of 90-120 minutes per meeting and good attendance rate. It also involves
making commitments concerning the chairman, collaboration with pharmacists,
preparation, agenda and minutes (9) (Table 1).
Table 1: Characteristics of peer review groups related to organizational structure
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Goals and Consensus
Another important issue is a common goal and the intention of reaching consensus.
This may seem easy; a major goal of each PRG is to improve pharmacotherapy, but
the interpretation and intensity can be very different (from merely exchanging
information to developing binding consensus on therapy and testing adherence to
guidelines). PRGs are generally considered to evolve from information exchange
towards more binding agreements, (5,9) and the goals of each are related to how
long the peer review group has been in existence (10). The more binding the
meetings and the agreements are, the more effective (5). In our questionnaire we
inquired as to the goals of the PRGs and about attitudes regarding consensus of
prescribing (Table 2).
Table 2: Characteristics of peer review groups related to goals and consensus
Preparation and Presentation
Style of presentation influences the outcome of PRG meetings. The use of
complaints, diagnoses and cases as topics appears to work better than theoretical
lectures that cannot easily be implemented in practice (9). The use of feedback data
(prescription audit) or a formulary is important aspects of preparation and
presentation to achieve behavioral change. Questions on how groups actually
prepare and present meetings are summarized in Table 3.
Analyses
Starting with the PRG characteristics thought to be most relevant for the
modification of effects of our intervention we used the results of the questionnaire
to model combinations of stratification factors on the total number of strata and
the number of PRGs in each stratum. Finally, we made a choice of stratification
factors based on relevance and distribution. 
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Table 3: Characteristics of peer review groups related to preparation and presentation
After completion of our randomized trial the Poisson regression model was used to
estimate Incidence Rate Ratios (IRRs) of anticholinergic antidepressants in the
intervention arms versus the control arm. These IRRs were estimated for six
different strata. These strata were formed by dichotomizing the whole data set
three times. First, a stratification of PRGs based on the presence or absence of
binding consensus. Second, stratification on the use of feedback data or not. Finally,
a stratification on the presence or absence of a formulary. In Egret, IRRs were
estimated after correcting for sex and baseline incidences, using baseline incidences
as an offset variable. 
RESULTS
Response
Of the 61 PRG representatives that were contacted, 40 (66%) cooperated. Six
preferred to fill out the questionnaire at home, four of which were returned. Nine
did not want to participate because of lack of time or interest, six were on holiday,
two could not be reached for other reasons and two did not want to mention why
they declined to cooperate. 
Questionnaire
Organizational Structure
There was great variance in how long groups existed (0.5-25 yrs.) and the number of
members (4-21). There was less variation in the attendance rate (60-100%) and the
number of meetings per year (4-10). Most PRGs sprung forth from groups that
shared night calls (85%). Some PRGs had contact with other PRGs (18%), invited
speakers (26%) or had contact with hospital specialists (33%) (Table 1).
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Goals and Consensus
More than one answer could be provided for the question on goals. Ninety-five per
cent (95%) defined one of the goals as the exchange of information regarding
pharmacotherapy. Eighty percent reported discussing current prescribing, 78%
giving advice, and 65% making agreements on pharmacotherapy. Only 26%
reported testing these agreements (Table 2). 
Preparation and Presentation
Lectures were the most popular format for meetings, followed by case discussion
and the use of prescription data (Table 3). Over half (22 PRGs) used an existing
primary care physicians formulary, but only nine were working towards a
formulary of their own. Feedback data of any kind were used by 22 PRGs. Sixteen
groups reported to use both an existing formulary and feedback data.
Stratification
Characteristics of PRGs potentially influencing the effect of an educational
outreach program were thought to be related to organizational aspects, the aim of
the group and preparation and presentation. 
The results of the questionnaire showed that minimal requirements for structure as
described in Dutch literature on PRGs (5-8) were fulfilled. Therefore, we decided
not to use this part of the questionnaire for stratification.
Besides organization, the aim of a group is potentially relevant for stratification.
Based on theory and responses we decided that the stated aim of the groups might
be an important PRG characteristic that might influence the outcome of the
intervention. We therefore dichotomized the PRGs into those which did not go
further than information exchange versus those which worked with binding
consensus. All groups that indicated that the aim was to make agreements were
considered to be on the level of binding consensus (26 PRGs). The rest was
allocated to the level of information exchange. 
We chose the use of a formulary and the use of feedback data as two other
characteristics warranting stratification. We interpreted the use of a formulary as an
intention to rationalize prescribing. We considered experience with feedback data
relevant for our intervention, as the outreach program would include feedback of
prescription data.
At this point we had 8 (2*2*2) strata. After distribution of PRGs into these groups,
all but one stratum would contain at least three PRGs (Table 4).
To evaluate the characteristics we used for our stratified randomization we
compared the outcome of the educational outreach program for groups with and
without these characteristics (Table 5). The effect estimates show that all three
characteristics modified the effect of our outreach program. Although our overall
analysis showed that our outreach program influenced prescribing (a reduction of
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anticholinergic antidepressants of 31%, 95% confidence interval 5-50%, p=0.022)
(3) this reduction was not observed when PRGs were selected on the use of binding
consensus, no use of feedback data and no use of a formulary. 
Table 4: number of peer review groups after distribution over selected characteristics of PRGs thought to be 
relevant for the effect of an educational outreach program on prescribing behavior
Table 5: incidence rate ratios (IRR)# of anticholinergic antidepressants of the intervention arms versus the control arm within
characteristics of PRGs which were used for the stratified randomization
Data <> information     Stratification of dutch peer review groups
92
DISCUSSION
This study reports on the selection process of characteristics of PRGs thought on
theoretical ground to be relevant for the responsiveness of an educational outreach
program on prescribing behavior and the control afterwards whether the selected
characteristics modified the effect of our intervention. Our results show
retrospectively that it was indeed relevant to distribute the characteristics we had
selected equally over the treatment arms. However, this study does not show that
these were the most relevant characteristics to select. There may be other known
or unknown characteristics, which have an important modifying effect on our
intervention. 
Literature about the qualities of PRGs that might facilitate goal achievement
(improvement of quality of pharmacotherapy) is scarce. We therefore used research
and theories on the effectiveness of PRGs to assess and distribute potential relevant
characteristics. More general theories on the diffusion of innovations conclude that
diffusion is fundamentally a social process, and emphasize the importance of
network interconnectedness (affiliation with a hospital, office-sharing and
sociometrical position) (13). 
Some limitations to our approach should be considered. Response to the telephone
interview was 66%. Thirteen representatives did not want to be interviewed. They
may have caused response bias, as most of these (nine) indicated a lack of interest.
This was partly because their group had not yet started or had only just started.
Another reason brought up was that PRGs were too much in focus; some
professionals claimed to be tired of all this attention. Interviews were conducted
with group representatives, who may have been more motivated and more
enthusiastic about the meetings than other group members.
Because not all groups wanted to or were able to cooperate with the prior inventory
of characteristics of PRGs, the stratification was based on available information.
For our randomized trial we randomly assigned groups that had not been
interviewed over the intervention arms.
Despite the emphasis on organizational structure of PRGs in the literature, we
thought it not necessary to use it for our stratification. In most PRGs, basic
requirements for structure were fulfilled. This may be due to the fact that
accreditation for post-academic training has been attached to the organization of
PRG meetings in the Netherlands. 
We found that groups that work on the level of binding consensus were less
receptive to our intervention strategy. An explanation may be that these groups
take more time to change prescribing because they first have to reach a new
consensus on the subject. As we have no data on the long-term effect of our
intervention, we could not evaluate this hypothesis.
The use of a formulary indicates an intention to rationalize prescribing, but it can
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also cause a different effect: there are already guidelines on the subject of
intervention. This may make it more difficult to influence prescribing.
Unexpectedly, we observed that we were not able to change prescribing in groups
that did not work with a formulary. 
Experience with feedback data was not only relevant because it was part of our
intervention strategy to change prescribing, but it can also be considered as an
intention to arrive at a consensus. Anticholinergic antidepressant prescribing in the
elderly decreased more strongly in groups familiar with feedback data. Further
research is needed to find out whether this is an important factor for groups to be
maximally receptive to educational programs. 
Our findings indicate that for future educational interventions it may be necessary
to use several tailored strategies depending on the characteristics of the PRGs
Although we realize that our choice is partly subjective, we think that in an
educational outreach program on a group level, stratification is superior to plain
randomization. We chose factors that seemed relevant for our outreach program.
Other interventions or PRGs with other characteristics may require another set of
factors for stratification.
We conclude that although many aspects of continuing medical education are not
yet well understood it is possible and relevant to do a stratified randomization in an
educational outreach program where the level of intervention is a group of
professionals. In this paper we used characteristics of PRGs found in the literature.
It is important to further identify relevant characteristics by comparing groups in
which prescribing altered versus groups in which this was not the case. 
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HOOFDSTUK 7 
Het voorschrijven van sterk anticholinerge antidepressiva bij ouderen
verminderen: een gerandomiseerde interventie van individuele en
groepsgewijze nascholing
Doel van de interventie
In dit hoofdstuk wordt de interventie beschreven. Verbetering van de kwaliteit van
het voorschrijven van antidepressiva aan ouderen door huisartsen, dat was wat we
met deze interventie wilden bewerkstelligen.
Maar waarom? Dat we gekozen hebben voor ‘antidepressiva bij ouderen’ was min of
meer toeval, zoals wordt toegelicht in hoofdstuk 2 en 3. De database van de
zorgverzekeraar kon ons de benodigde gegevens verschaffen, de discussie over ‘oude’
en ‘nieuwe’ antidepressiva was actueel, en er leek inderdaad wat te verbeteren aan
het voorschrijfgedrag.
Maar een ander motief lag aan deze doelstelling ten grondslag. We leven in een snel
veranderende wereld waarin nieuwe kennis en veranderde inzichten met betrekking
tot behandelwijze en farmacotherapie elkaar razendsnel opvolgen. Artsen en
apothekers moeten op de hoogte zijn van deze ontwikkelingen, én de veranderingen
implementeren in hun beleid. Er worden verschillende methoden toegepast om
nieuwe kennis aan artsen en apothekers over te brengen. Er wordt postacademisch
onderwijs gegeven, er worden kwaliteitsprojecten geïnitieerd en er worden
richtlijnen geformuleerd. Maar wat blijkt? Het publiceren van resultaten van
studies of het rondsturen van richtlijnen is nauwelijks effectief. In de praktijk
leiden al deze inspanningen niet tot het gewenste resultaat, namelijk
gedragsverandering van behandelaars. 
Welke aanpak is dan wel effectief? De farmaceutische industrie heeft een lange
staat van dienst als het gaat om gedragsbeïnvloeding van artsen. De farmaceutische
bedrijven investeren er veel geld in, en ze zijn er goed in. Maar de industrie heeft
uiteraard zo haar eigen belangen. Een door de farmaceutische industrie veel
gebruikt instrument om producten ‘in de pen te krijgen’, kortom: om artsen te
beïnvloeden, is ‘de artsenbezoeker’, die in een één-op-één contact de dokter
probeert te overtuigen van de voordelen van een bepaald geneesmiddel.
Een andere effectieve manier om een doelmatig voorschrijfbeleid tot stand te
brengen is de werkwijze van FTO-groepen: huisartsen en apothekers bespreken
gezamenlijk hun kennis en inzichten en verbinden daar in veel gevallen
consequenties aan voor de uitoefening van hun praktijk. 
Het eigenlijke doel van onze interventie was te onderzoeken hoe voorschrijfbeleid
beïnvloed kan worden. Daarvoor ontwikkelden we deze campagne: de interventie.
Het verbeteren van het voorschrijfbeleid van antidepressiva aan ouderen was daarbij
middel, en geen doel op zich.
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Utvoering van de interventie
We wilden een vergelijking maken tussen de effecten van een campagne op
individueel niveau (analoog aan de activiteiten van een artsenbezoeker) en op FTO-
niveau (dus het geven van groepsgewijze voorlichting). 
Zowel tijdens de individuele bezoeken als in de FTO-groepen hebben we aan de
artsen verteld dat het ons doel was hen alert te maken op de kwetsbaarheid van
ouderen voor anticholinerge geneesmiddelen. Vooral bij de behandeling van
depressiviteit is het belangrijk daar rekening mee te houden, omdat antidepressiva
die veelvuldig aan ouderen worden voorgeschreven vaak sterk anticholinerg zijn.
Tijdens de individuele bezoeken en bij de FTO-groepen zijn dezelfde punten
besproken, gedurende twee bijeenkomsten met ongeveer drie maanden tussenpoos.
Afhankelijk van de tijd en de reactie bespraken we het volgende: Eerst de
veranderde manier waarop ouderen op geneesmiddelen reageren, de verhoogde
gevoeligheid van ouderen voor bijwerkingen en waarom het belangrijk is om
anticholinerge middelen bij ouderen te vermijden. Verder hoe lastig het kan zijn om
een depressie te herkennen bij ouderen en dat er op dit moment in hun regio (het
onderzoeksgebied, de Zuid-Hollandse eilanden) meer anticholinerge antidepressiva
aan ouderen dan aan jongeren worden voorgeschreven. 
Om het effect van de individuele bezoeken en het bezoeken van FTO-groepen goed
te vergelijken, hebben we de eenentwintig FTO-groepen over drie armen verdeeld,
elk met zeven FTO-groepen. Door loting werd bepaald, welke groep op welke
manier benaderd zou worden.
Uit de eerste arm van zeven FTO-groepen is niemand benaderd, er is geen
interventie gedaan. De artsen uit deze arm fungeerden als controlegroep. De artsen
uit de tweede arm zijn allen individueel bezocht. De artsen uit de derde arm zijn in
hun FTO-groepen benaderd. Op deze manier zijn 43 huisartsen en 14 apothekers
individueel bezocht. Daarnaast zijn 52 huisartsen en 9 apothekers via het FTO
gezien. Hiervoor waren meer dan 110 visites nodig, waarvan slechts 7 aan FTO-
groepen.
CONCLUSIE
Het resultaat van de interventie was, dat de bezochte artsen na het bezoek
daadwerkelijk minder anticholinerge middelen voorschreven aan ouderen. Uit de
analyses bleek geen duidelijk verschil in effect tussen de individuele en de
groepsbezoeken. Een groepsbezoek is dus een efficiënte manier van nascholing.
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Reducing highly anticholinergic
antidepressant use in the elderly: 
a randomised trial of group vs. 
individual "academic detailing"
A modified version has been published in
the British Medical Journal 322 (2001) 654-657
Martine E.C. van Eijk, Jerry Avorn, Arijan Porsius,
Anthonius de Boer
So he bent down, put his head into the hole, and called out:
"Is anybody at home?"
There was a sudden scuffling noise from inside the hole, and
then silence. 
"What I said was, ‘Is anybody at home?’" called out Pooh very
loudly.
"No!" said a voice; and then added, "You needn’t shout so
loud. I heard you quite well the first time."
"Bother!" said Pooh. "Isn’t there anybody here at all?"
"Nobody." ……….
A.A. Milne, Winnie-the-Pooh, 1926. 
Chapter: Pooh goes visiting, page 21.
Abstract
Context: With the development of ever more effective and
costly medical technologies, more needs to be known about the
best methods to disseminate and implement that knowledge.
Objective: To compare the effect of individual educational visits
versus group visits on prescribing, using academic detailing. For
this comparison our focus was to reduce the use of highly
anticholinergic antidepressants in the elderly.
Design: Randomized controlled trial with three arms (individual
visits, group visits and a control arm).
Setting and Participants: General Practitioners (190) and
pharmacists (37) organized in 21 Peer Review Groups in the
Southwest Netherlands were studied using a database covering
all prescriptions to persons insured by national health insurance
in this area (approx. 240,000). 
Intervention: All General Practitioners and pharmacists in both
intervention arms were offered two educational visits. For
physicians randomized to the individual visit arm, 43 of 70
General Practitioners participated; in the group visit
intervention arm, 5 of 7 groups (41 of 52 General Practitioners)
participated. 
Main Outcome Measures: Incidence (starters) of highly
anticholinergic antidepressants and less anticholinergic
antidepressants by treatment arm.
Results: Using an intention-to-treat analysis, we found a 26%
reduction in the incidence of initiation of highly anticholinergic
antidepressants in the elderly (95% CI, -4%-48%) in the
individual intervention and 45% (95% CI, 8%-67%) in the group
intervention arm. In addition, the use of less anticholinergic
antidepressants in the elderly increased by 40% (95% CI, 6%-
83%) in the individual intervention and by 29% (95% CI, -7%-
79%) in the group intervention arm.
Conclusions: Both the individual and the group visits decreased
the incidence of initiating highly anticholinergic antidepressants
and increased the incidence of less anticholinergic
antidepressant use in the elderly. These approaches are practical
means for continuing medical education to improve prescribing.
Keywords: health care peer review, randomized controlled trials,
data collection, drug therapy, continuing medical education,
drug utilization review, antidepressive agents, aged
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INTRODUCTION
In the face of an increasing need to improve rational prescribing, many questions
still remain unanswered on how best to achieve this goal (1-3). 
Educational visits have been proven effective to modify professional behavior (4,5).
They should consist of repeated personal visits, including feedback, presenting clear
practice-relevant recommendations and anticipating any implementation problems
(6-9). Not all characteristics of effective visits have been identified (4,10).
Collaboration of doctors and pharmacists in regional groups is an increasingly well
accepted method of improving prescribing in several countries (1,11-13) and can be
a cost-effective platform for the dissemination of new knowledge and guidelines.
The purpose of this study was to evaluate the effect of these two different
approaches to influence the prescribing of physicians: the impact of individual
visits vs. group visits, both with the use of academic detailing. 
Antidepressants in the elderly was selected as a focus for the study because former
analyses of dispensing data (14) and other studies (15) have shown that a substantial
portion of patients over the age of sixty were prescribed highly anticholinergic
antidepressants, despite their potentially greater risk of hazardous side-effects such
as dry mouth, blurred vision, constipation, urinary dysfunction, hypotension,
tachycardia, and cognitive impairment(16-23). We wanted to increase the awareness
of the vulnerability of the elderly to anticholinergic side effects and decrease the
prescribing of highly anticholinergic antidepressants in this group (e.g.tertiary
amine tricyclics), while encouraging the use of less anticholinergic antidepressants
when indicated, such as secondary amines or selective serotonin re-uptake
inhibitors.
METHODS
Study Design
We conducted a randomized controlled design to compare the effect of individual
vs. group educational visits on the prescribing of higly anticholinergic
antidepressants in the 60+ population. To organize the group visits we used an
existing system of Peer Review Groups which foster collaboration between Dutch
pharmacists and General Practitioners. These groups of professionals, practicing in
the same region, meet regularly to discuss treatment, pharmacotherapy and patient
management. Similar initiatives are seen in other countries and are known as
quality circles, pharmacotherapy discussion groups or pharmacotherapy
consultation groups. The goals of these groups include: exchanging information,
policy advising, agreement on guidelines, and using feedback methods to measure
adherence to these(11-13). Prior to the intervention these groups were surveyed on
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factors thought to be relevant for the intervention (see below). Based on this survey,
groups were matched prior to randomization. Matching variables were: (a) stated
goals of the group (binding consensus vs. other goals) and (b) the use of a formulary
or feedback data vs. neither. We used a block randomization to assign all groups to
one of three intervention arms. In the individual intervention arm each General
Practitioner was offered individual educational visits. In the group visit
intervention arm this was offered to each Peer Review Group as a whole. The
control arm received no visits.
Research Area
The research area (the South Holland Islands) is part of the area of the health
insurance company ‘OZ zorgverzekeringen’ (Mutual Care health insurance) in the
Southwest Netherlands. This region is a mix of semi-rural and rural areas. The
population is approximately 400,000, 60% of which (240,000) are insured through
‘OZ zorgverzekeringen’. 
Research Population
The research population comprised all people over 60 years old (approximately
50,000 elderly), living in the Southwest Netherlands health district and insured
through ‘OZ zorgverzekeringen’(table 1).
We performed a pre-study sample size calculation and found that 7 peer review
groups (with an average 2,000 patients over 60 per peer review group and 22
patients starting an anticholinergic antidepressant over a time period of 1 year) per
treatment arm were enough to demonstrate with 80% power a statistically
significant (p<0,05) reduction of 30% in prescribing of anticholinergic
antidepressants.
Databases
Prescribing of antidepressants was measured using the reimbursement databases
that pharmacists send to the health insurance company monthly. These contain
information on all drugs dispensed to insured patients: amount, dosage, costs, and
date of issue, as well as information about the user’s insurance number and
birthday and the prescribers’ code. All reimbursable drugs for the insured
population, are registered this way(14,24).
Drug Classification
We classified the following agents marketed in the Netherlands as highly
anticholinergic antidepressants: amitriptyline, clomipramine, doxepin, imipramine
and maprotiline (table 2).
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Table 2: Drug Classification
Intervention
The intervention was designed following theories and experience usually referred to
as social marketing or academic detailing (4-6,10). It is a framework for
dissemination and implementation of prescribing improvement activities and refers
to a combination of adult learning theories and the marketing experience of the
pharmaceutical industry, but directed at improving the rationality of prescribing.
All doctors and pharmacists from groups assigned to the individual visit
intervention arm were individually contacted by telephone. They were told of the
aim of the study (to improve antidepressant prescribing in the elderly and measure
the effectiveness of an educational program), and they were invited to participate in
the program. For those who agreed, an appointment was made for a twenty-minute
visit with the lead investigator (MvE), a physician. This session emphasized the
unique therapeutic difficulties of the aged and the problems of anticholinergic side
effects in the elderly, using a hand-out flyer containing an evidence-based summary
of the most important information. 
To decrease the use of highly anticholinergic antidepressants in the elderly, all
sessions were based on a priority list for issues to be discussed. Depending on the
length of the visit and the responses of the professionals, these items were
discussed in order: 1/ altered pharmacodynamics and kinetics in the elderly (18,19)
2/ increased vulnerability for side-effects in the elderly (20,21) 3/ the need to avoid
anticholinergic antidepressants in the elderly (22) and 4/ difficulties in diagnosing
depression, especially in the elderly (17). Overall data of antidepressant prescribing
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in the former year in the area were shown during the visit to illustrate that most
anticholinergic antidepressants are prescribed to people over 60 (14). The initial
visits included no further comment on personal performance. At the end of each
visit another appointment was made for approximately four months later. During
the second visit a graph was provided showing personal performance and the
fraction of anticholinergic antidepressant prescriptions versus less anticholinergic
antidepressant prescriptions in three age categories: under 60, 60-70 and over 70
years old. 
For the group intervention arm all group co-ordinators were contacted to ask
permission to use one full meeting for the educational program. The content of
these presentations was essentially the same as in the individual contacts. At the
end of the first visit, permission to use part of another meeting was requested. In
this second meeting, a graph of accumulated prescribing in the group was shown
and personal graphs were handed out. 
All contacts for both intervention arms were performed by one of the authors
(MvE). The control arm was not contacted.
Study Outcome
The effectiveness of this intervention is best reflected in antidepressant choice for
patients initiating therapy.
To define starters (incident users) of antidepressants, we used the prescription
reimbursement records described above. For each prescription we calculated the
number of days the prescription would cover using the PDD (prescribed daily dose)
and the package size (14). In this way, a time window of probable use was created.
We assessed all antidepressant prescriptions from July 1995 on. If there was no
former antidepressant prescription or if the interval exceeded 180 days, the patient
was considered an incident user (a starter) of either a highly anticholinergic
antidepressant or a less anticholinergic antidepressant (14). 
In the Netherlands all persons under National Health Insurance are allocated to a
general practitioner. Pre-, inter-, and post-visit periods were calculated for each
general practitioner in the region to allocate each starter to the right period per
general practitioner, to determine whether the start of the antidepressant was
before, between or after the sessions. In order to calculate incidence rates (number
of new starters / person years), the number of patient days per period was calculated
to determine the denominator. For the control arm and for non-participating
general practitioners (in the individual and group intervention arms), average
visiting dates were calculated for physicians not actually visited, based on those
actually visited and used to create a pre-, inter-, and post intervention period.
The incidence rates of highly anticholinergic antidepressants use and less
anticholinergic antidepressants use were calculated per General Practitioner per
period.
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Statistics
We used a Poisson regression model to estimate Incidence Rate Ratios (IRRs) of
starting highly anticholinergic antidepressants and less anticholinergic
antidepressants for the elderly in both intervention arms in relation to the control
arm. The evaluation was done on an intention-to-treat basis, so as not to
overestimate the effect of the intervention by including only the most responsive
physicians. Since randomization was performed on a group level and correlated
outcomes (within a group) can influence precision (95% CI) (25), we studied IRRs
with and without correction for correlated outcomes (exchangeable correlation
matrix), using a longitudinal data analysis (Spida). This did not materially influence
outcome. Point estimates were virtually identical and 95% confidence intervals
changed less than 3% (there was no change in statistical significance of effects
estimates).
Since it was not possible to correct for baseline incidences in Spida, we used Egret,
although in this program it is not possible to analyze correlated Poisson outcomes.
In Egret, IRRs were estimated after correcting for sex and baseline incidences, using
baseline incidences as an offset variable. The effect of the first and second visits
and of both visits together were estimated. The effects in each intervention arm
and of both interventions together were also measured.
RESULTS
Overall, 190 general practitioners and 36 pharmacists were working in the research
area. Sixty-nine per cent of the general practitioners and 100% of the pharmacists
in the intervention arms were visited (table 3). In the individual visit intervention
arm, 86% of the professionals visited were visited twice. The request for a second
appointment after the first visit was always granted, but did not take place on
seven occasions, because the first possible date was after the closing date of the
intervention. The average time spent per person was 14.6 minutes in the individual
visit intervention arm. In the group visit intervention arm only one group (14%)
was visited twice. Most groups first wanted to decide together whether and when
they were going to join the program. Well organized Peer Review Groups had their
agenda planned for the entire season, while other groups were glad to have one (or
two) meetings organized by an academic researcher. This caused large differences
between groups in contact time (from 15 min. once to a full hour twice). Further
details on general practitioners, pharmacists and visits are listed in Table 3. 
The total number of 60-96 year-olds in the research area was 46,078, 58% of whom
were female. Baseline incidence rates of highly anticholinergic antidepressant use
were lower than the incidence rate of less anticholinergic antidepressants (Table 1). 
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Table 3: Baseline Characteristics of General Practitioners and Pharmacists
Baseline incidences differed between treatment arms. In both intervention arms the
incidence of anticholinergic antidepressants for patients aged ≥ 60 decreased during
the study period, while in the control arm the incidence actually increased (Figure
1). Table 4 shows IRRs of anticholinergic antidepressants after correction for
baseline incidence rates and sex. All estimates showed a reduction in the
prescribing of highly anticholinergic antidepressants in the intervention arms
compared to the control arm. This reduction was more than 30% after two visits in
the individual visit intervention arm (A) and more than 40% in the group visit
intervention arm (B). This decrease was significant for the group approach and for
the combined effect of both interventions. 
In both intervention arms the incidence of less anticholinergic antidepressants for
patients ≥ 60 years increased during the study period, while in the control arm the
incidence decreased (Figure 2). In the individual visit intervention arm, elderly
subjects were 100% more likely to start antidepressant treatment with a less
anticholinergic antidepressant in the post-intervention period (Table 4). In the
group visit intervention arm this was almost 70%.
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Figure 1: incidence of initiation of less anticholinergic antidepressants in te 60+ population, before, during and after
educational visits (intention to treat)
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Figure 2: incidence of initiation of highly anticholinergic antidepressants in te 60+ population, before, during and after
educational visits (intention to treat)
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DISCUSSION
We have shown that both individual visits and group visits can effectively improve
the clinical appropriateness of prescribing behaviour in an area of suboptimal
prescribing: the treatment of depression in the elderly. Both interventions had a
similar effect not seen in the controls: elderly people starting antidepressant
treatment received less anticholinergic medication more often. The group visits
significantly decreased the use of highly anticholinergic antidepressants and the
individual visits significantly increased the incidence of less anticholinergic
antidepressants in older patients. The combined effect of both intervention arms
was also significant.
Reasons for non-participation were diverse. For the group intervention it was
mainly a time problem. Most finally agreed, but in some cases the intervention
period had already ended. For the individual visits reasons mentioned were;
shortage of time, this study should be initiated by the medical faculty instead of
the faculty of pharmacy, just not motivated.
The data reported probably represent a lower-bound estimate of the potential of this
approach. Anticholinergic versus non-anticholinergic antidepressant prescribing
remained a topical issue in the given time period (26-29). Despite the fact that we
focused our intervention on anticholinergic antidepressant use in the elderly, this
controversy might have diluted the effect (30).
We think the observed changes over time are not due to a "regression to the mean"
effect. The statistical analyses adjusted for the different baseline incidence rates.
Next to that, for regression to the mean to occur, it usually requires the selection of
a sample because it has an unusually high (or low) set of values for a given variable.
The groups studied were not defined or chosen on this basis.
Tricyclic antidepressants are used not only for depression, but other indications as
well, such as chronic pain syndromes. Their use for other such indications may also
have had a diluting effect on our intervention. The effectiveness of the intervention
was probably also diluted by prescriptions initiated by psychiatrists or other
specialists who were not part of the intervention, since we allocated all incident
cases to their General Practitioner.
This study contains no long-term evaluation of the effectiveness of our
intervention, yet other studies have shown that repeated interventions are needed,
for sustained behavioral changes. It can be assumed this approach will also be
effective for other drug categories. In groups, two opposing processes can influence
the effect of an outreach programme on prescribing. Groups can be more effective
in accomplishing tasks (31), and to publicly announce behavioral changes results in
more commitment than to do so privately. In this way, behavioral changes can be
facilitated by the group approach. Psychological research into group behavior has
produced an inventory of factors that influence conformity with group standards
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(32). Unanimity provides more pressure to conform, while privacy makes it easier
not to. On the other hand, as there is rarely unanimity in medicine, obstacles can
be expressed easily in these meetings, and more barriers against the new strategy
might be expressed in a group than in a one-to-one setting. The implementation of
new knowledge is facilitated by expressing and discussing how to overcome
obstacles to its acceptance. This may occur more intensely in groups than in an
individual learning setting.
Further research in group learning processes in health professional groups may
reveal valuable information on factors that facilitate the dissemination and
application of new knowledge about pharmacotherapy.
Audit and feedback are becoming increasingly important to help professionals keep
up with evolving knowledge and to actively implement it in their practices. The
present study adds to our knowledge of educational programmes in daily practice.
Group approaches are likely to be a useful and cost-effective addition to the arsenal
of academic detailing approaches used to improve evidence-based prescribing.
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HOOFDSTUK 8 
Effect van de interventie op patiënt niveau gemeten
Wie werd er beter van deze interventie?
Onze interventie had succes: in de interventiearmen was het voorschrijven van
anticholinerge middelen aan patiënten boven de zestig sterk verminderd.
In dit hoofdstuk wordt beschreven wat het effect van de interventie op
patiëntniveau was. Het gaat tenslotte om de patiënt: het beïnvloeden van het
voorschrijfgedrag van artsen is bedoeld om het leven van patiënten aangenamer te
maken. 
Er zijn weinig studies waarbij niet alleen de effecten van een interventie op het
voorschrijfgedrag van de arts onderzocht is, maar waarbij ook is gekeken is naar
patiënten. Waren die er eigenlijk wel bij gebaat? 
We gebruikten hiervoor dezelfde vragenlijsten als beschreven in hoofdstuk 4 en 5.
Om te weten hoe het met de gebruikers van antidepressiva ging nadat wij de artsen
benaderd hadden, verstuurden we nog een enquête. Met behulp van de ingevulde
vragenlijsten hebben we na de interventie onderzocht of patiënten uit de
interventiearmen ook daadwerkelijk minder last van bijwerkingen hadden in
vergelijking met patiënten in de controlearm, waar geen interventie had
plaatsgevonden. 
De gemelde bijwerkingen in de interventie- en de controlearmen voor en na de
interventie evaluerend, kwamen we tot de conclusie dat de patiënten niet beter,
maar ook niet slechter zijn geworden van de veranderingen in het voorschrijven van
artsen. Dit kan liggen aan geringe respons of aan de schaal van het onderzoek of aan
gebrekkige indicatoren. Misschien hadden we andere vragen moeten stellen.
CONCLUSIE
We denken dat het zinvol is de effecten van een interventie op patiëntniveau te
meten. In ons onderzoek wijst niets erop dat patiënten er slechter van zijn
geworden.
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8
Evaluation of patient outcomes in an area
in which the prescribing of anticholinergic
antidepressants was successfully reduced
by academic detailing
submitted for publication
Martine E.C. van Eijk, Svetlana V. Belitser, Arijan Porsius,
Anthonius de Boer
By the time it came to the edge of the Forest the stream had
grown up, so that it was almost a river, and, being grown up, it
did not run and jump and sparkle along as it used to do when it
was younger, but moved more slowly. For it knew now where it
was going, and it said to itself, "There is no hurry. We shall get
there some day."
A.A. Milne, The house at the Pooh corner, 1928. 
Chapter: Eeyore joins the game, page 89.
Abstract
Objective: To evaluate, on a patient level, the effect of
an intervention that successfully reduced anticholinergic
antidepressant prescribing in the elderly. 
Design: Cross sectional surveys with questionnaires
send prior to and after our intervention 
Setting: South Holland islands, the area in which we
performed in 1996 a randomized controlled trial to study
the influence of an intervention on prescribing behavior.
Participants: Elderly patients (age between 60-95 years)
who used antidepressants in 1995 and 1996 in our
research area according to a Health Insurance
prescription database. 
Main Outcome Measures: Prevalence of adverse events
related to antidepressant use, severity of depression and
quality of life have been compared in users living in the
intervention and control areas. 
Results: Prior to our intervention we send 2359
questionnaires of which we could use 827 (35%) for
analysis. At baseline, there were no statistically
significant differences between the intervention and
control areas. After the intervention 3375 questionnaires
were send of which 939 (28%) could be used. The
occurrence of dry mouth and coughing and the amount
of pain were lower in the intervention area compared to
the control area (p<0.05).
Conclusion: We found no indications that adverse
events, severity of depression and quality of life was
changed in an unfavorable direction, when comparing
patients living in an area in which the prescribing of
highly anticholinergic antidepressants was successfully
reduced to patients living in an area in which the
prescribing of antidepressants was not intentionally
changed.
Keywords: patient outcome measures, questionnaires,
adverse events, depression, elderly, COOP/WONCA
charts
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INTRODUCTION
Most programs that intend to rationalize prescribing evaluate their effectiveness by
looking at prescribing volumes. There is increasing attention for economic
evaluation of treatment strategies and interventions to rationalize prescribing (1-3).
The need to include patient outcome measures has been mentioned before, but is
not often practiced (4-6). Recently we published the results of a randomized
controlled trial in which we compared the effect of individual educational visits
and group visits versus no visits on prescribing of antidepressants in primary care
(7). The focus of the study was to reduce the use of highly anticholinergic
antidepressants in the elderly in which we succeeded. During the study the
prescribing of anticholinergic versus non-anticholinergic antidepressants remained
a topical issue (8-10). On the one hand there was a consensus report published on
behalf of the Dutch association of general practitioners (‘NHG-standaard’) (11) in
which tricyclic antidepressants were presented as first choice drugs for the
treatment of depression. On the other hand, there was a consensus report which
was prepared by consultants of different disciplines (psychiatrists, geriatricians, etc)
(‘CBO-consensus report’) (12) in which serotonin re-uptake inhibitors were
presented as first choice compounds. Given the controversy on the subject, and the
lack of information on how elderly react to these drugs (13)we decided, next to the
collection of prescription data, also to collect data on patient outcomes. This
manuscript reports on the effects on a patient level of our successful intervention:
reduction of the prescribing of highly anticholinergic antidepressants in the elderly.
MATERIALS & METHODS
Design
To measure patient outcomes we performed two cross sectional surveys.
Questionnaires were sent to elderly antidepressant users living in the area where
we performed the randomized controlled trial, (7). Questionnaires were sent prior to
and after the performance of the trial. 
Short details of the trial
The participants in the study were 190 general practitioners and 37 pharmacists
organized in 21 Peer Review Groups in an area covering approximately 50,000
elderly. The 21 Peer Review Groups were equally divided in an individual
intervention arm, in a group visit intervention arm and a control arm (no visits).
Our intervention followed theories and experience usually referred to as academic
detailing. The focus of the study was the reduction of highly anticholinergic
antidepressants in the elderly. The outcome of the study was that in both the
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individual and group arm the prescribing of highly anticholinergic antidepressants
was reduced (26% and 45%, respectively) while the prescribing of less
anticholinergic antidepressants was increased (40% and 29%, respectively)
compared to the control arm.
Setting 
The project was performed in a research area that is part of the area of the health
insurance company 'OZ zorgverzekeringen' in the Southwest Netherlands.
Approximately 240,000 people (60% of the population in the research area) were
insured through 'OZ zorgverzekeringen' of which 50,000 were 60 years of age or
older.
Participants
During the first survey (prior to the intervention study) all elderly people (60-95
years of age) in the research area who had used an antidepressant during the year
prior to the survey (1995) were invited to participate in our questionnaire survey.
During the second survey (after the intervention) all elderly who were selected for
the first survey were again asked to participate. Furthermore, during the second
survey we invited all elderly who had newly started an antidepressant during the
year of the intervention study, 1996, (and thus were not asked to participate during
the first survey) to participate. Of this last group of elderly only one questionnaire
(after the intervention) is available. 
Questionnaire
The questionnaire contained questions about general patient characteristics (sex,
age, marital state etc.), medical state (including a list of known side effects and
complaints, related to antidepressants and depression), medical consumption, the
Geriatric Depression Scale (14) and the COOP-WONCA Health Charts (15).
Procedures
Patients were identified using the reimbursement databases that pharmacists send
to the health insurance company. Patients who had at least one prescription of an
antidepressant (defined as a drug with ATC code N06A or N06CA01) reimbursed in
1995 were selected (16). Questionnaires were send to patients by the health
insurance company with pre-stamped return envelopes. For the second survey all
patients invited to participate in the first survey were again asked to participate.
Furthermore, patients who had newly started an antidepressant in the
reimbursement databases during the intervention study were also send a
questionnaire after completion of the trial. 
A short letter in which the aim of the survey was explained accompanied the
questionnaire. The aim mentioned was the evaluation of drug use in elderly,
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adverse events and well being of elderly using drugs. We emphasized the limited
information that is collected from experimental drug trials and the importance of
surveys on the effects of drugs in the elderly in daily practice. No special attention
was given to antidepressants nor to the prescribing interventions we performed in
the research areas.
Analysis
Our intervention (to reduce the prescribing of highly anticholinergic
antidepressants in the elderly) was directed at prescribers and pharmacists. This
report focuses on the outcome of patients (adverse events, symptoms related to
depression and general well being) in the areas in which the intervention was
performed versus the control area. We decided to perform an intention-to-treat
analysis. Thus, not only the patients of the most responsive physicians were
included in the analysis but all patients of all physicians in the intervention areas
and control area. 
The reduction of the prescribing of highly anticholinergic antidepressants, as
intended by our intervention, could occur in two ways. First, the reduction could
occur in patients newly prescribed an antidepressant. Second, in patients already
using highly anticholinergic antidepressants, a switch to less anticholinergic
antidepressants could take place. So far, we only evaluated the effect of our
intervention on the incidence of initiating highly and less anticholinergic
antidepressants and not the effect on switching of antidepressants (7). The latter is
expected to occur less or later than the effect on new starts of antidepressants
("Never change a winning team"). 
In the light of this, and the fact that of the patients newly started on an
antidepressant no baseline questionnaires were available, we decided not to
compare the change in patient outcomes (post intervention minus baseline
outcomes). We compared post-intervention patient outcomes separately for all
patients in the intervention areas versus all patients in the control area and for
patients newly started on an antidepressant in the intervention areas versus
patients who newly started an antidepressant in the control area. 
Descriptive statistics of the baseline questionnaire are presented in order to be able
to evaluate whether possible post-intervention differences were already present
prior to the intervention.
Dichotomous patient outcomes (e.g. the presence of adverse events) were evaluated
by logistic regression. Effect estimates were adjusted for age and sex differences in
the intervention versus the control groups.
Ordinal patient outcomes (scores of COOP/WONCA) were analyzed by linear
regression (adjustment for age and sex differences) and expressed as mean difference
and 95% confidence intervals.
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Results
In our first survey in 1996, prior to the intervention study, we sent questionnaires
to 2,359 users of antidepressants in 1995 of which 945 were returned (40%). Fifty-
eight of these questionnaires had too many missing values and 60 were answered
by another family member than the one addressed, leaving 827 (35% of 2,359)
questionnaires that could be used for our data analysis. 
For the second survey in March 1997, after completion of our intervention study,
the patients that were sent a questionnaire during the first survey (n=2,359) and the
patients that used an antidepressant in 1996 and not in 1995 (new starters of an
antidepressant; n=1,016) were sent a questionnaire. Of these groups the response
rates were 719 (30% of 2,359) and 314 (31% of 1016), respectively. For our data
analysis on the level of all patients we were able to use 939 (28% of 2,359 plus
1,016) questionnaires and for the analysis of new starters of antidepressants, 101
(9.9% of 1016) questionnaires. Reasons for the reduction of 1,033 questionnaires to
939 were major omissions in the answers of the questionnaire (n=64) and answering
of the questionnaire by another family member (n=30). The reduction of the 314
questionnaires to 101 was caused by answering the questionnaire by a family
member (n=18) and the start of the antidepressant prior to the date on which the
patient's general practitioner was visited for the intervention meeting (aimed to
change the prescribing of antidepressants) (n=195). In the patients of the control
area, the mean date of the visited general practitioners in the intervention areas
was used.
Tables 1 to 3 show the number of adverse events and complaints related to
depression and antidepressant use reported by the (former) users of antidepressants
in the research area, before and after the intervention. Table 3 relates to the new
starters of antidepressants in the research area. Prior to the intervention, there were
no statistically significant differences in baseline characteristics. After the
intervention only dry mouth, coughing and amount of pain was reported
significantly less (p<0.05) in the intervention area, compared to the control area.
Other patient outcome measures, including overall well being and quality of life
questions from the COOP/WONCA charts post-intervention showed no significant
differences between the control and intervention area (Table 4).
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Table 1: baseline characteristics of patients living in an area in which a randomized controlled 
trial was performed to reduce the prescribing of highly anticholinergic antidepressants*
Table 2: outcome of patients in an area in which the prescribing of highly anticholinergic 
antidepressants was successfully reduced (intervention) compared to a control area (control)
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Table 3: outcome of patients who newly started an antidepressant in an area in which the prescribing of highly 
anticholinergic antidepressants was successfully reduced (intervention) compared to a control area (control)
Table 4: COOP/WONCA prior to and after the performance of a randomized clinical trial in which the prescribing of highly
anticholinergic antidepressants was successfully reduced in the intervention area (intervention) compared to the control area
(control)
DISCUSSION
Due to the low response rate of patients, our study results have to be interpreted
cautiously.
When we assume that there is no to minor selection bias. This study demonstrated
that in an area in which the prescribing of antidepressants in the elderly was
intentionally changed towards less prescribing of highly anticholinergic
antidepressants and more prescribing of less anticholinergic antidepressants, the
well-being of patients who used or recently had used antidepressants was
comparable to similar patients in an area in which this prescribing intervention
was not executed. Except for less complaints of dry mouth, coughing and amount of
pain in patients in areas in which the intervention took place compared to the
control area, the occurrence of adverse events, complaints related to depression, the
seriousness of depressed feelings and the scores of different domains of quality of
life were comparable.
Response rates in both surveys were low (28-35%). These rates were lower than
expected when compared with similar surveys. In retrospect there may be several
reasons for low response besides the general tendency of more and more people to
refuse to participate in questionnaire surveys. First, the questionnaire was
relatively long, especially for an elderly group (60-95 years in our surveys). It is
possible that, the explanation of the total study (including our intervention study)
and more information about other projects by our institute, would have increased
response rates; however, this information might also have influenced patient
responses (information bias). 
Our comparison of responders and non-responders revealed no important
differences for several general patient characteristics. Although this might point at
minor selection bias in our study results, this interpretation is speculative.
Furthermore, the relative small sample size and the uncertainty of confounding
bias (not all prognostic factors of different outcomes were available) further limits
the interpretation of the study results.
Although our statistically significant differences can be due to type I error (we
performed 90 statistical comparisons), an interesting finding was that in the
intervention areas the occurrence of dry mouth was lower that in the control area.
This finding was in accordance with the reduction in the prescribing of highly
anticholinergic antidepressants in the intervention areas. This finding was
statistically significant when all patients were analyzed together and not when the
analysis was restricted to the patients newly started on an antidepressant, although
the same tendency (less occurrence of dry mouth) was observed. 
Our study design and the way we analyzed the data show the difficulties one
encounters when patient outcomes are to be evaluated in a study in which the
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intervention was directed at the prescribing of general practitioners. Decisions have
to be made concerning intention-to-treat versus a per protocol analysis, correction
or not for baseline findings, evaluation of only patients using antidepressants at
baseline and post-intervention or also including patients that recently have used
antidepressants, evaluating post-intervention data of only patients that newly
started an antidepressant during the intervention period versus evaluation of all
patients that used at baseline or have recent past use of antidepressants et cetera.
Prior to the start of the study we thought the most relevant patient data would be
baseline and post- intervention data of patients that newly started an
antidepressant during the intervention period. However, a simple and practical
solution for the collection of the baseline questionnaire was obviously not possible,
especially in the control area in which the general practitioners and pharmacists
were not contacted.
Conclusion
Although this study has methodological limitations and a low response rate, we
have no indications that the well-being, adverse events, severity of depressive
feelings and quality of life was changed in an unfavourable direction, when
comparing patients living in an area in which the prescribing of highly
anticholinergic antidepressants was successfully reduced to patients living in an
area in which the prescribing of antidepressants was not intentionally changed.
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HOOFDSTUK 9 
Samenvatting en algemene overwegingen 
Er is een groeiende behoefte aan wetenschappelijk verantwoord medisch handelen.
Om dit te ondersteunen worden richtlijnen opgesteld met behulp van de resultaten
uit onderzoek. Dat dokters deze richtlijnen gebruiken, is echter niet vanzelfspre-
kend. Er wordt dan ook veel aandacht besteed aan manieren waarop artsen gesti-
muleerd kunnen worden deze richtlijnen te volgen. Dit proefschrift beschrijft
diverse aspecten van dit proces. Het laatste hoofdstuk speculeert over hoe nascho-
ling er in de toekomst uit zou kunnen zien. Wat zou de rol kunnen zijn van de
grote databases bij kwaliteitsanalyses, medische besluitvorming, kennismanage-
ment en voortdurende nascholing? Met dit hoofdstuk willen wij een aanzet geven
tot het denken en discussiëren over de rol van grote gegevensbestanden en de
Informatie Communicatie Technologie (ICT) binnen de gezondheidszorg.
In de toekomst zal er steeds meer informatie beschikbaar zijn over artsen en
patiënten. Dit kan ernstige inbreuk maken op onze privacy en veel ellende
veroorzaken. Het kan echter ook de gezondheidszorg ondersteunen, wanneer we
daarvoor kiezen.
Uit onderzoek naar het gebruik van vernieuwingen blijkt dat deze nieuwe
structuren nodig maken. Elke nieuwigheid beïnvloedt de bestaande processen. Zo
volgde op de uitvinding van de auto een behoefte aan betere wegen, vervolgens
kwam er de mogelijkheid om verder van het werk te wonen en veranderde
uiteindelijk onze hele houding ten opzichte van mobiliteit. Zo zal ook nascholing
veranderen en kunnen overgaan in voortdurende nascholing door de enorme
toename van (beschikbare) informatie. Niet iedere keer dat uit onderzoek blijkt dat
de behandeling van een aandoening verbeterd kan worden, zal hierover een
programma worden opgezet. Er moet een soort continu proces van samenwerking,
communicatie, kwaliteitsanalyse en kennismanagement ontwikkeld worden. Er
zullen interdisciplinaire platforms van steeds wisselende samenstelling ontstaan,
waarin voortdurend informatie beheerd en gewogen wordt. Hoe deze er precies uit
gaan zien, weten we nog niet, maar het zal belangrijk zijn dat alle partijen (patiën-
ten, zorgverleners, universiteiten, zorgverzekeraars et cetera) hieraan deelnemen en
dat ieders belangen bekend zijn en gewogen kunnen worden. We zullen anders
moeten omgaan met informatie, communicatie en samenwerking. We zien nu al
dat ICT de wereld zal veranderen. Het internet forceert deze vernieuwingen; me-
dische kennis en hulp, overal vandaan, zijn beschikbaar als nooit tevoren. Hoe de
nieuwe gezondheidszorg er precies uit zal zien, zal blijken in de volgende decennia.
Wat zijn de kansen en uitdagingen van deze nieuwe tijd? In de kakofonie van
informatie waarin we terecht zijn gekomen, zullen behandelaars en patiënten hun
onderlinge relatie moeten veranderen. Met behulp van richtlijnen, losse informatie
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en individuele kenmerken moet steeds een passend behandelplan gekozen worden.
Artsen en patiënten zullen samen, in een open dialoog, een keuze maken.
Apothekers kunnen hier een belangrijke rol in gaan spelen. Hoe kunnnen we in de
toekomst alle informatie wegen? Iedereen kan zijn of haar ideeën via het internet
beschikbaar stellen. Dat is één van de uitdagingen die er ligt in de toekomst: welke
informatie is betrouwbaar? In dit verband is het in ieder geval een voorwaarde dat
er geen verborgen belangen zijn. Daarnaast zullen de medische en de
farmaceutische opleidingen zich minder moeten richten op het leren van feiten en
meer op het leren wegen van informatie, en het ontwikkelen van een attitude van
voortdurende reflectie en verbetering. 
Hoe kunnen we zorgen dat ICT de gezondheidszorg ondersteunt? In de toekomst
hebben we mensen nodig die graag informatie delen en met kritiek kunnen om-
gaan. Daarnaast moeten we een enorme hoeveelheid technische problemen oplos-
sen; systemen moeten beter kunnen communiceren, gegevens en kennis moeten
beschikbaar zijn voor iedereen, maar privé-informatie moet privé kunnen blijven.
We moeten leren met een enorme hoeveelheid informatie om te gaan en goede
zoekstrategieën te ontwikkelen. Als dat lukt kunnen kwaliteitsanalyse, commu-
nicatie, kennismanagement en het maken van een behandelplan samen gaan vallen.
Hoe is de relatie tussen grote databases, kwaliteit van zorg en het implementeren
van vernieuwingen? Diagram 5 laat zien hoe we een overvloed aan informatie uit
registraties kunnen gebruiken in een soort continu proces van ‘inzoomen’ en
‘uitzoomen’ om kwaliteitsprojecten te ondersteunen. Allereerst kan er op
macroniveau gekeken worden wat er gebeurt en wat er opvalt. Vervolgens kunnen
we zoeken naar gebieden waar kwaliteitsverbetering mogelijk is en deze
specificeren. Daarna kunnen we het probleem kwantificeren en zo op de agenda van
de betrokkenen proberen te krijgen. Daarbij kunnen we met behulp van data
concrete doelen formuleren om een interventie te ondersteunen. Ook kunnen we
de informatie voor de betrokkenen inzichtelijk maken op individueel niveau (zoals
bijvoorbeeld prescriptieterugkoppeling, maar iets dergelijks kan ook voor patiënten
gemaakt worden). Dit laatste kunnen we dan ook gebruiken om te (laten) zien of de
gestelde doelen bereikt zijn. Daarnaast kunnen we onderzoeken waarom we onze
doelen al dan niet gehaald hebben, wat het effect op andere variabelen is en wat we
van dit project kunnen leren voor toekomstige projecten.
Er zijn nog veel vragen over alle aspecten van kwaliteitsprojecten in de zorg. Hoe
definiëren we optimale zorg? Op welke manier stimuleer je die? Hoe kunnen we de
grote medische registraties onderhouden zonder de privacy in gevaar te brengen?
Wat is de ideale interventie?
Laten we hier nog lang en kritisch over discussiëren.
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9
Summary and 
Final Considerations
"When you wake up in the morning, Pooh," said Piglet at last,
"what’s the first thing you say to yourself?" 
"What’s for breakfast?" said Pooh. "What do you say, Piglet?" 
"I say, I wonder what’s going to happen exciting to-day?" said
Piglet.
Pooh nodded thoughtfully.
"It’s the same thing," he said.
A.A. Milne, Winnie-the-Pooh, 1926. 
Chapter: We say Good-bye, page 144.
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SUMMARY
There is a general trend to work towards a more evidence based medical practice.
To support this, an increasing number of guidelines are being developed to translate
new evidence to medical practice. The implementation of guidelines, however, is a
complex process described in various behavioral models. These models have
influenced health behavioral projects and pharmaceutical marketing and so found
their way into academic detailing as used in this research. Still, doctors'
compliance to guidelines varies widely and there is no general agreement about the
most effective way to support doctors implementing new guidelines. This thesis
compares two methods (individual visits versus group visits) aimed at improving
the quality of pharmacotherapy. Reimbursement data were used to provide
quantitative information to support the methods. We used the regionally organised,
typically Dutch, peer review groups (PRGs) of primary care physicians and
pharmacists to address professionals. In addition we included patient outcome
measures to evaluate the effect of our program on both doctors' performance and
patients' well being. Chapter 1, the introduction, describes the state of the art in
the diffusion of innovations, the use of reimbursement data for research, and how
to define –and how to measure– the quality of prescribing and how to measure
patient outcomes. To optimally design the diffusion of an innovation, many aspects
have to be taken in account. Chapter 2 is about the assessment of the quality and
suitability of our data. We describe a systematic tool to test the appropriateness of a
given database for specific research questions. It gives insight into data collecting
and data quality, relevant for both researchers and interpreters of similar
investigations. We describe in particular the potency and the pitfalls of
reimbursement data and express our belief that these data need to be protected and
valued more and should be handled with care. This is the challenge: striking the
balance between reckless utilism and respect for the individual. Chapter 3 is the
description of how we used the reimbursement data to assess the quality of
prescribing of antidepressants to the elderly. At the time, much discussion went on
about the advantages and disadvantages of the newer antidepressants and the
vulnerability of the elderly to anticholinergic drugs. We used reimbursement data
to assess whether physicians avoid prescribing highly anticholinergic
antidepressants to the elderly. We therefore analyzed the drug choice for new users
of antidepressants only (incident users) to avoid contamination of the results with
patients that are "happy" with a drug, as it can be difficult for physicians to change
medication for these patients. We have demonstrated that the elderly are still
prescribed highly anticholinergic antidepressants and that it is possible to assess
incident prescribing with reimbursement data. We decided to designate this a
benchmark for our intervention on prescribing behavior. The incidence rates would
be more illustrative for physicians than basic prescribing volumes. Chapter 4
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compares the prevalence of complaints mentioned by users of anticholinergic
antidepressants to a control group of former users of antidepressants in a population
of ambulant elderly, in order to relate prescribing to patient outcome. Because there
is evidence that highly anticholinergic drugs can be harmful to the elderly, we
decided to assess patient related outcome measures prior to the intervention. We
sent a questionnaire to all users of antidepressants over 60 years in the research
area. This questionnaire inquired as to basic characteristics (sex, marital state,
smoking, alcohol use etc.), medical condition and medical consumption. The
Geriatric Depression List, the VROPSOM, Rand-36 and the COOP-WONCA Health
charts were also included. Could we confirm results from randomized controlled
trials in our study of the elderly? To our surprise, we found no evidence that elderly
using highly anticholinergic drugs suffer more adverse events. Community-
dwelling elderly using highly-anticholinergic antidepressants did not report more
adverse events than elderly using less-anticholinergic antidepressants. Moreover,
the number of adverse events in the antidepressant users was comparable with
what can be seen in former users of antidepressants. Confounding by
contraindication may explain these findings, as would be expected if prescribers
were aware of drug-specific adverse event risks and avoided or discontinued use of
problematic drugs in patients with such symptoms. In Chapter 5 we compared
several rating scales to assess depression, since inclusion criteria are considered to
be an essential element of good guidelines. (Under-)diagnosis of depression is
mentioned to be a problem in several studies; therefore, we also used the
questionnaires of the preceding chapter to evaluate depression scales. We were able
to establish a comparison of various validated rating scales scoring depression in a
group of ambulant elderly. The results show that the chance of a patient to be
diagnosed as depressed depends heavily on the rating scale being used. It remains a
challenge for future research to find new solutions as early diagnosis and treatment
of depression is important to restore optimal levels of functioning, quality of life
and independence, and to reduce societal costs. Chapter 6 describes another
essential factor for the intervention: How are PRGs functioning in the area? The
intervention design included validating the effect of individual visits versus PRG
visits. Using the existing knowledge on PRGs, we designed a questionnaire
including different aspects of organization, goals and preparation. We selected and
evaluated characteristics of PRGs that were thought to be relevant for the effect of
our outreach program. After the intervention we were able to demonstrate that
these factors (use of feedback data, use of a formulary, level of binding consensus)
did indeed modify the effect of our educational outreach program. When groups are
addressed in an intervention, it is relevant to assess basic characteristics of these
groups, either to use these for a block randomization or for correction in the
subsequent analyses. Chapter 7 describes the intervention we undertook to reduce
the prescribing of highly anticholinergic antidepressants in the elderly and its effect
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on incident prescribing. The intervention was designed following insights usually
referred to as academic detailing, an approach that has proven to be effective to
influence prescribing, which is usually used in an individual setting. We added a
group versus individual approach design, using PRGs. We have demonstrated that a
group approach can effectively change prescribing as well. In our intervention, we
found a 31% reduction in the incidence of initiation of highly anticholinergic
antidepressants in the elderly and a 36% increase of the use of less anticholinergic
antidepressants. Many countries are looking for models for continuous medical
education. Addressing groups may be an important tool to support acceptance of
new guidelines. More research in group-learning processes is needed to improve our
understanding of continuing medical education. Chapter 8 compares the question-
naires of elderly using anticholinergic antidepressants, living in the intervention
and control areas, to measure the effect of our intervention on a patient level.
Besides the patient questionnaire mentioned above, we sent a similar questionnaire
after the intervention. We found no indications that well-being, adverse events,
severity of disease and quality of life had been changed unfavorably in patients
living in the intervention arm areas, compared to patients living in the control arm
area. Unfortunately, neither did we observe an increase in quality of life for patients
in the intervention arm area. The scale of the study might not have been large
enough to measure such a result on a patient level. Besides this summary, Chapter
9 includes some final considerations, in which we speculate on what continuous
medical education might look like in the future. What will be the role of very large
medical information databases in quality assessment and continuous education? It
aims at stimulating to think ahead –and to take action– on employing ICT
(Information and Communication Technology) for the benefit of health care.
FINAL CONSIDERATIONS
Future perspective; accumulated accessible information
New technological developments will open up opportunities to assess and analyze
accumulated information on patients and doctors. This accumulated, accessible
information can change the world into a nightmare of loss of privacy and intimacy,
can result in inequality, and can make us alienated, cold and distant. But it can also
support equal and accessible health care for everyone, if we want it to (1-4).
New insights require new organizations
Research on diffusion of innovations has evolved from examining natural diffusion
of innovations through supporting diffusion and acceptance of innovations to
individuals, to the organizational consequences of innovations. There is an
increasing awareness that organizational variables act on innovation behavior in a
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manner over and above that of the aggregate of individual members of the
organization (5,6). The implementation of (technical) innovations in an organization
amounts to a mutual adaptation of the innovation and the organization. Typically,
each one changes during the subprocess of the implementation (7). "Innovations not
only adapt to existing organizational and industrial arrangements, but they also
transform the structure and practice of these environments" (Van de Ven, 1986).
From continuous to ongoing medical education
In the future we do not want to plan and design an intervention for each area of
sub-optimal prescribing, or each time new knowledge or evidence results from
research. We need to reorganize health care in such a way that health care providers
and users (patients, clients) work together continually. We need to communicate, to
share knowledge and to work on quality assessment and improvement of care as an
ongoing process of information management (8,9). Interdisciplinary platforms of
medical cooperation may communicate and work together rapidly in constantly
changing platforms. Anybody can be the center of a platform at some time.
Different people will be actively involved, depending on the topics discussed.
Patients and doctors will be able to make well-informed, shared decisions (8-10).
The exact structure and organization of these platforms will probably evolve over
the next few decades. The role played by patients, insurance companies, the
pharmaceutical industry and the government is not yet clear. All conflicts of
interest (as there are always conflicts of interest) need to be revealed and handled in
a systematic and open way (11,12).
ICT will change the world
A new attitude towards cooperation, communication, information and knowledge
sharing will be accelerated by new developments in Information and
Communication Technology (ICT). Already we can see some of the impact that ICT
will have on medical care. In the decades to come we will have to shape and build
this new style health care. It is not clear yet what it will look like, but the ICT
revolution has passed its point of no return and will have an enormous impact on
every aspect of our lives in the near future. The Internet creates transparency and
equality and challenges historically grown hierarchical structures. Patients already
have access to online medical journals and can exchange information and
experiences. This has made medical information available to laymen as never
before (13). This, combined with vanishing distances (consulting doctors from the
other side of the world or discussing with patients suffering the same complaints
wherever they are is easy), will change the patient-doctor relation dramatically (3).
Any patient, certainly the one with the means to pay, will be able to withdraw
herself from governmental control or the agreements and guidelines of the medical
profession in her physical environment (13).
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Opportunities and challenges
This new situation of total equal access to information will force a change in the
doctor-patient relation (3). They have landed on a planet of cacophony, where they
will need each other to decide on the best possible treatment strategy for each
specific situation. This wil include going through a complex process of risk
assessment, taking into consideration ones set of genes, environment, character,
social network, lifestyle and history (14). Computer-assisted execution of guidelines
(including personalized patient information leaflets, checklists, prescriptions,
documentation and laboratory protocols being processed after putting in a tentative
diagnosis) and availability of information will change medical work into a
combination of rapid routine jobs and advanced case management that will
continuously update a doctor’s medical knowledge (8,15). We will have to redefine
what constitutes good medical care (including pharmacotherapy) in a world where
everybody is an individual. At times, patient and doctor will be searching for and
evaluating evidence and other information together and come to shared decision-
making in an open dialogue (15). Even for lots of routine problems, this process will
keep the doctor constantly alerted to new information and new guidelines (8,9).
Some of this may seem scary; as we all know, anyone (any fool, idiot or professor)
can find someone to agree with her or him. In the future there will be a website to
support any awkward opinion. This will be one of the challenges before we can
maximize the potential benefits of ICT to health care: we need ways to define and
to give insight to credibility of (online) health information (13) (9). This requires at
least a completely open system of decision-making where no hidden conflicts of
interest are tolerated. In addition to the integrity of available information, we need
tools to find our way in times of chaotic information overload (13). Every medical
school, every patient organization and every governmental and non-governmental
health organization will set up an online library of guidelines, key lectures,
publications, discussion platforms and benchmarks (10). We need special medical
search tools to find relevant and reliable information quickly (15). We need
professionals that can help people to find their way. Pharmacists can play an
important role here. Following this online consumer health information will not
only bring difficult questions to the doctors’ office; it can also bring us a well-
informed and motivated patient. We need to shift the emphasis of medical training
from learning data to learning to weigh information, to communicate, to achieve an
attitude of continuous learning, self-reflection, collaboration and a desire for self-
improvement (16). 
A clear advantage of online education will be the accessibility of this information
for doctors, pharmacists and patients in remote areas. An important condition to
meet this advantage is equitable access across the globe. Everyone should be able to
get online and all relevant information should be available online. 
Tele-consultation will be another opportunity created by new communication
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techniques, to combine improved patient care and continuous medical education.
Another important challenge will be to balance privacy and connectivity, to protect
the individual and support the community. Techniques that will enable secure and
mobile data processing in health care have to be improved. We need quality control
and intellectual property agreements. This will require new laws with international
validity.
It may happen that online professionals will relieve the practitioner from some
routine jobs, but differences between virtual and face-to-face interaction will never
make a physician jobless.
How can we make ICT support health care?
In the future, good health care will be provided and supported by people with an
open attitude towards information sharing and criticism. The speed of new
developments, the complexity of medical decision-making and the high economic
and emotional value of possible conflicting interests, all require a revolution to be
able to provide rational health care for everyone in the near future (15). 
Our great challenges are that: We will have to solve an enormous number of
technical problems and to agree on definitions to make systems able to
communicate. It is possible that in the future, all systems will be integrated. We
have to find ways to make individual information accessible for all that are eligible
to use this information and none that are not, balancing utilism and respect for
individual privacy. We need to share health care and knowledge with the rest of the
world (including all the poor). We have to find ways to deal with the information
overload that will be a direct result of these developments and we will have to
solve problems on credibility of information. We need new techniques for the
retrieval of relevant and reliable medical information rapidly.
The greatest challenge of the new millennium will be to bring about a change of
attitude that will make health care providers and consumers emphasize long-term
goals and believe in equality of all parties involved. In this changing world, post-
academic training will finally be continuous medical education in a true sense,
where quality assessment, communication, case and knowledge management and
shared decision-making meet. 
Large databases, quality of care and diffusion of innovations
One of the initiating questions of this research was; how can we support quality of
pharmacotherapy with the aid of reimbursement records? To achieve optimal
medical care (including optimal prescribing) we need (among many things) good
guidelines, which are evidence based, regularly updated ànd good programs for
continuous medical education (17-36).
Medical registration, whether reimbursement data, questionnaires or other
registrations, can support this in several ways. Diagram 5 sketches the relation of
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diagram 5
The relation of large databases and diffusion of innovation
*Specific
Measurable
Achievable
Realistic
Time-related
macro level
what happens?
micro level
where can we
increase quality?
personal / practice
feedback
make SMART* goals
what is the
exact problem?
what is it about?
which patients
and doctors
are involved?
what is the effect in
SMART* goals?
why have we
not / partly
completely
made our goals?
effect on other
parameters?
what can
we learn
from this
for future
projects?
large databases and diffusion of innovations as a continuous multilevel quality
project that requires drilling down and drilling up again and again, shifting between
macro- and microlevel. Firstly, data can help us to monitor prescribing and analyze
pharmacotherapy (what happens). Secondly, we can detect areas of sub-optimal care
and locate specific problem domains (where can we increase quality and who is
involved?) (8,37-43). After this, we can use these databases to help to quantify the
problem and put it on the agenda of involved parties. Following that, we can use
data to define SMART (= specific, measurable, achievable, realistic and time-
related) goals and support an intervention by giving feedback (24) and to assess the
effect of an intervention, on prescribing, on a patient level or on other parameters
(44-48). Our study demonstrates that these data can support quality of care, but also
that we need to protect our data to make this possible (carefully balancing the
possible harm and benefit that can be done with these data) (49-67).
Alongside the reimbursement data, we used questionnaires to assess quality of
prescribing at a patient level. This may add valuable information on the effects of
medication when used in "real life". After assessing quality of prescribing both at a
patient and a doctor level (expressed in SMART goals), why should we include
patient outcome measures if the intervention is evidence based and scientifically
proven to be the best for patients (effect on other parameters)? The evaluation on a
patient level of an intervention to increase evidence based prescribing is in a way
an evaluation of the guidelines themselves. Is this necessary? Yes- we think one
should aim at evaluating the guidelines as well in an ideal intervention. Reasons for
this are that constantly new knowledge will evolve, patient benefits can be
measured on an endless number of levels, consumer populations are different from
trial populations, and circumstances are constantly changing. All this may force us
to update guidelines. Further, what is beneficial for individuals can be in conflict
with what is best for all, as is the case for short and long-term goals. We need to
aim at projects that will include quality assessment at all levels (8,68-77). How do
the doctors, patients and the guidelines perform (what can we learn from this
project)?
We conclude that many questions still remain on all aspects of the process of
diffusion of innovations. What is the best way to improve quality of care? What
actually is to be defined as optimal prescribing, in individual cases, on a population
level, on the long and short term? Which methods of feedback are most effective?
How do we maintain large medical databases without jeopardizing privacy? How
can we use these databases in a preventive way (e.g. post-marketing surveillance)?
What constitutes an ideal intervention?
Please enjoy my unfinished thoughts.
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Dankwoord
This would be my present to you, my friends, 
If it weren't your gift to me.
(vrij naar A.A. Milne)
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De weg die begint als je gedragen in je moeders schoot het ritme van het leven leert
kennen en die als het goed is eindigt als je gedragen door je achterkleinkinderen
eindelijk stopt met verdergaan, is te lang om iedereen die je gesteund, verder
geholpen en getroost heeft, te bedanken. Kleine gebaren van mensen die je
onderweg even tegenkomt kunnen de rest van je pad soms meer beïnvloeden dan
anderen die je langdurig begeleidden. Ik weet niet waar ik moet beginnen met het
bedanken voor de rol die zo ongelooflijk veel mensen in mijn leven gespeeld
hebben. Ik voel mij een gefortuneerd mens, altijd zijn er mensen op mijn pad
geweest om me te steunen en te sturen. Die me namen zoals ik ben en die me
hielpen mezelf en mijn weg te accepteren voor wat het is. Ik kan alleen maar hopen
dat het zo verder zal gaan. Toch wil ik enkele groepen die me begeleid hebben en
plaatsen waar ik geweest ben noemen. Te beginnen met mijn werk want daar gaat
dit boekje over. 
OZ zorgverzekeringen heeft de moed gehad om een groot project te starten met een
ver doel. Jullie hebben samen met de Universiteit mij gevraagd om te kijken hoe we
de kwaliteit van voorschrijven zouden kunnen ondersteunen met de aanwezige
declaratiegegevens (kijken wat we met die data kunnen doen). We dachten allemaal
dat dat een redelijk simpel traject zou zijn, maar toen dat anders uitpakte zijn jullie
niet van gedachten veranderd en dit project blijven steunen voor zover dat binnen
jullie mogelijkheden lag. Beleidsinformatie halen uit produktiegegevens is een
proces dat betrekking heeft op de hele organisatie, neem daarbij enkele fusies,
verhuizingen en reorganisaties en dan komt er een beeld van de hoeveelheid
medewerkers van OZ die mij heeft moeten helpen en waar ik heel fijn mee heb
samengewerkt. Zonder jullie openheid, enthousiasme en steun was dit boekje nooit
afgekomen. Dank jullie wel! Dankjewel Theo voor het initiëren van dit project,
dankjewel OZ, houd dat lef in werken en respect voor de turbulente omgeving
waarin jullie opereren. Bert, Berthe, Bob, Cees, Conny, Désirée, Erwin, Han, Harm,
Jan, Leni, Linda, Patrizia, Petra, Roebertha, Rini, Rolf en Ruud (De alfabetische
volgorde doet jou geen recht!) bedankt voor het vertrouwen, alle geduldige uitleg en
gezelligheid. 
De disciplinegroep Farmacoepidemiologie en Farmacotherapie van de faculteit
farmacie was naast OZ zorgverzekeringen, mijn basis gedurende bijna acht jaar.
Deze groep is in die tijd flink uitgegroeid van een kleine groep enthousiastelingen
die lang niet door iedereen begrepen werd tot een grote groep met gewicht...... Dat
is de buitenkant van de sectie (zoals ik het zal blijven noemen). De binnenkant is
een hele diverse club bezielde mensen. Het is stimulerend om in zo’n groep te
mogen werken en ik hoop dat iedereen die er deel van uitmaakt zich dat terdege
realiseert. We gingen kijken wat we voor leuke dingen met die data konden doen,
we hebben ons verdiept in hoe we wat leuks met die data kunnen doen. Ik vond het
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heerlijk om jarenlang van gedachten te mogen wisselen over mijn werk met
intelligente en positieve collega's en studenten, daarvoor moet ik jullie allemaal
bedanken. Ton, jij was een rots in de branding, elke keer als ik het echt niet meer
zag zitten bleef je vol goede moed en hielp me verder. Dank je, ik kan me bijna niet
voorstellen dat het straks echt af is. Arijan, op een gegeven moment was ik bang
dat jij de Universiteit eerder mocht verlaten dan ik, en dat is min of meer gebeurd.
Geniet van je nieuwe activiteiten en dank je voor alles. Bij fepi hebben Hong Sang,
Gert, Rob en Ron me een gezellige start gegeven en ingewijd in SQL. André,
Angela, Anke Hilse, Annette, Arsenio, Audrey, Aukje, Bart, Bert, Cees, Charles,
David, Eugene, Geurt, Hamid, Hanneke, Hans, Hilka, Igor, Jan, Jan, Jeannette,
Joëlle, José, Lyda, Marcel, Marieke, Miranda, Nelly, Olaf, Patrick, Rolf, Svetlana,
Thijs, Toine, Tom, Welmoet en Willem (Wie ben ik nu nog vergeten?), jullie waren
heerlijke collega's, waardoor ik altijd weer met plezier naar het Wentgebouw ging.
Ik ga jullie missen.
Alle, en dus ook deze twee organisaties hebben, hoe dynamischer ze zijn en hoe
meer werkplekken de medewerkers hebben, behoefte aan een stabiele kern. Voor
die stabiliteit zorgt het management, maar ook voor een heel groot deel de
secretariële staf. Zonder jullie geregel en continue aandacht voor absolute en
randvoorwaarden had ik niet zoveel dingen tegelijk kunnen doen. Daarom wil ik
jullie even noemen, Dankjewel Addy, Berry, Carla, Conny, Christine, Cinta, Erica,
Ineke, Nicole, Pien en Suzanne. Soms als ik na een nacht met niet bijster veel slaap
stond te stofzuigen voor ik naar mijn werk ging was het moeilijk om in dit boekje
te blijven geloven, gelukkig waren er dan Linda's relativerende lachsalvo's (en af en
toe een sigaretje).
Professionally I was also supported by Jerry Avorn. I kept telling myself that if
some Harvard Medical School scholar believed in my project, it had to be
something. Thank you for all your valuable comments and mental support, which
helped to make this project really nice to work on and improved its quality. 
De leden van de leescommissie ben ik ook speciale dank verschuldigd. prof. H.G.M.
Leufkens, prof. J. Avorn, mw. prof. F.M. Haayer-Ruskamp, mw. prof. T.J. Heeren en
prof. A.W. Hoes, heel erg bedankt voor het snel beoordelen van mijn manuscript. 
Alle complimenten aan de teams waar ik in heb mogen werken ten spijt, dit boekje
was nooit afgekomen als ik niet ook privé de mogelijkheden en de ruimte had
gekregen om me te ontplooien. Daarvoor wil ik allereerst mijn ouders danken, die
me de talenten en het gevoel van vertrouwen in de wereld om me heen hebben
gegeven, waar ik altijd zoveel profijt van heb. Ik hoop nog lang met jullie over deze
wereld te filosoferen, uitgedaagd en gesteund te worden op mijn weg. Inmiddels ben
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ik deel van een eigen gezin. Lambert, Lizette en Charlotte, voor jullie is het
regelmatig opschuiven en inschikken door mijn ambities. Dat ging altijd zonder
mokken of grote problemen, dat is een wonder, want het pad was heel zwaar de
laatste tijd. Ook ik neem me als zoveel promovendi voor dat het anders zal zijn na
de grote dag. Ik denk dat dat moet. Jullie aanwezigheid is een geschenk.
Op deze plek wil ik verder graag gebruik maken van de mogelijkheid om mijn
familie, vrienden, buren, behulpzame schoolmoeders, mijn schoonmoeder (dank
voor heel veel praktische, logistieke en morele steun), mijn broers Peter en Jeroen
en schoonzus Rinske (die er onder andere voor zorgde dat mijn kinderen goed in de
kleren zaten) en sommige toevallige passanten te bedanken. Jullie hebben allemaal
grote en kleine daden verricht door af en toe een handje uit te steken en vooral met
heel veel oppaswerk dit boekje helpen realiseren. Als promoverende moeder kun je
nu eenmaal niet alleen je partner bedanken, maar moet je hele sociale systeem op
het ereplateau. Er gaat niets boven een luisterend oor en samen lachen of huilen (en
ja natuurlijk heb ik jullie verwaarloosd.....). Sommige van jullie ken ik al mijn hele
leven, anderen volg ik pas sinds ik in de Braamstraat woon. Soms zijn het de buren
waarmee je je zorgen en plezier deelt, of die een handje uitsteken, soms je familie.
Samen zorgen jullie voor kwaliteit van leven in dit aardse bestaan. 
Dit boekje was er echt nooit gekomen als niet heel veel mensen me geholpen
hadden. Op het laatst nog schoten Ellen en Annemieke te hulp om mij te helpen in
gewoon Nederlands uit te leggen waar ik al die tijd mee bezig ben geweest. Dat was
een hele uitdaging. Zonder jullie was het niet zo goed gelukt. Ellen Wiggemansen
heeft op het laatst wonderen verricht door het DTP-en op zich te nemen, IOU! 
De meeste promotieprojecten zijn te groot om iedereen te bedanken die van
essentiële waarde is geweest. Hoe meer mensen ik bedank, hoe meer mensen ik
onterecht oversla. Hoe minder ik zeg, hoe meer recht ik doe aan alle onbenoembare
elementen. Sommigen weten wellicht zelf niet eens hoe en wanneer hun
aanwezigheid en steun van essentieel belang was. Truus en Ellen, jullie zijn
vandaag mijn paranimfen en iedereen kan zien hoe jullie mij fysiek bijstaan. Dat is
wat mij betreft symbolisch voor het gevoel dat jullie mij altijd hebben weten te
geven; achter mij te staan. Obrigado! Wie ik onterecht vergeten ben te noemen,
nodig ik uit me op te bellen. Dan gaan we een borrel drinken om te vieren dat deze
monomane marathon eindelijk uitgelopen is. 
Onderweg heb ik ook nog een belangrijke vriend verloren. Ik had helemaal op jouw
aanwezigheid gerekend, Peter. We hebben elkaar leren kennen toen dit project net
begonnen was. Helaas heb ik voor het afronden afscheid moeten nemen van je. Dat
is onvoorstelbaar, maar toch waar. Bedankt voor al je hulp en lieve humor. "Never
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make anything simple and efficient when a way can be found to make it complex
and wonderful".
Ik wil ook niet nalaten om alle patiënten, artsen en apothekers die mij belangeloos
hebben geholpen te bedanken voor hun aandacht en tijd. Het is altijd maar de vraag
wat eruit komt als je je subject stelt voor een onderzoek, ik hoop dat ik jullie niet
heb teleurgesteld (behalve in tempo). Verder kan ik het niet nalaten alle
medewerkers van andere betrokken organisaties zoals de softwarehuizen, andere
universiteiten, andere zorgverzekeraars, belangenverenigingen, koepels et cetera te
bedanken. Zij richtten hun blik op de kracht van samenwerking en kennisdelen in
plaats van op de macht van het alleen doen en alleen weten.
Tenslotte mijn nieuwe werkgever, DGV, het is fantastisch om alles waar ik de
afgelopen jaren mee bezig ben geweest nu vanuit een andere invalshoek te mogen
gebruiken. Die kans kon ik niet laten liggen. Wat ik terugkreeg was een team van
professionals die een gezamenlijk doel voor ogen hebben; ondersteuning van het
rationaliseren van de kwaliteit van farmacotherapie in Nederland. Jullie hebben de
laatste hobbels helpen nemen, ALLEMAAL heel erg bedankt. Ik zie uit naar werken
bij DGV zonder "dat boekje" als last op mijn schouders.
Wat kan een mens in 8 jaar overkomen: 7 chefs, 6 computerssystemen, 5
adreswijzigingen, 4 bevallingen (Lizette, Charlotte, Lambert’s proefschrift en het
mijne), 3 contracten, 2 keer naar een uitvoering van "L'Incoronazione di Poppea" in
de Stopera en gelukkig slechts één man: Lambert. While I run around in a Tiggerish
kind of way, you simply love me.
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Curriculum vitae
Martine van Eijk werd geboren op 23 juli 1962 te Rotterdam. Na het behalen van
haar VWO diploma aan het Strabrecht College te Geldrop in 1983, werd aanvang
gemaakt met de studie Geneeskunde aan de Vrije Universiteit te Amsterdam. Het
doctoraal examen werd afgelegd in 1989 en het artsexamen in 1991. In de periode
februari 1992 – oktober 1993 was zij werkzaam als arts van het GeneesmiddelTeam
voor VWS. Van november 1993 tot februari 1999 werkte zij voor OZ
zorgverzekeringen en aan het in dit proefschrift beschreven onderzoek bij de
disciplinegroep farmacoepidemiologie en farmacotherapie van de faculteit farmacie
te Utrecht (begeleiders prof. dr A.J. Porsius en dr A. de Boer). Sinds augustus 1999
werkt zij bij DGV Nederlands instituut voor verantwoord medicijngebruik.
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Enquête FTO-groepen
Naam huisartsengroep ............................................................................................................
Naam FTO-groep ............................................................................................................
Naam contactpersoon ............................................................................................................
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SAMENSTELLING FTO-GROEP
NAAM HUISARTS APOTHEKER ANDERS, NAMELIJK
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15.
1. In welk verband vindt het FTO plaats?
❏ huisartsengroep
❏ deel huisartsengroep, nl. gezondheidscentrum
❏ anders, nl. ..........................................................................................
2. Hoe lang komt de FTO-groep al bij elkaar?
❏ < 1 jaar
❏ 1-2 jaar
❏ 2-4 jaar
❏ 4-6 jaar
❏ > 6 jaar
3. Uit hoeveel personen bestaat de FTO-groep op dit moment?
.......... personen
4. Wat is de gemiddelde opkomst van de deelnemers?
❏ < 50%
❏ 50-70%
❏ > 75%
5. Wat is de frequentie van de FTO-bijeenkomsten?
❏ minder dan 5 keer per jaar
❏ 5-9 keer per jaar
❏ 10 keer per jaar of meer
6. Wat is meestal de duur van een FTO-bijeenkomst?
❏ 0,5-1 uur
❏ 1-1,5 uur
❏ > 1,5 uur
7. Is er in de groep expliciet gesproken over de doelstelling van het FTO?
❏ nee, reden: .........................................................................................
❏ ja
8. Welke algemene doelstelling heeft uw FTO?*
❏ informatie uitwisselen over geneesmiddelen en voorschrijfgedrag
❏ kritische reflectie op (eigen) voorschrijfgedrag
❏ elkaar adviseren over voorkeursbeleid
❏ afspraken maken over voorkeursbeleid
❏ toetsen van gemaakte afspraken
❏ anders, namelijk ...............................................................................
9. Door wie wordt het FTO voorbereid?
❏ apotheker(s)
❏ huisarts(en)
❏ huisarts en apotheker samen
❏ wisselend door apotheker of huisarts
❏ geen voorbereiding
* meerdere antwoorden mogelijk
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10. Wat wordt er voorbereid?*
❏ theoriestuk/voordracht
❏ casus
❏ concept-advies t.a.v. voorkeursmedicatie
❏ prescriptiecijfers
❏ anders, nl.  ........................................................................................
11. Maakt uw FTO een planning voor langere termijn?
❏ nee, reden: ........................................................................................
❏ ja voor hoe lang? ❏ half jaar
❏ 1 jaar
❏ > 1 jaar
wat wordt gepland?*  ❏ data
❏ onderwerpen
❏ de voorbereiders
❏ de gespreksleider
❏ evaluatie van het overleg
❏ anders, nl. ....................................
12. Bespreekt u het verslag van de FTO-bijeenkomst?
❏ nee, reden: ........................................................................................
❏ ja
❏ geen verslag gemaakt
13. Is er voor het FTO een gespreksleider aangesteld?
❏ nee
❏ ja ❏ huisarts
❏ apotheker
❏ anders, nl. .....................................
14. Is het gespreksleiderschap vast of wisselend?
❏ vaste persoon
❏ wisselend per keer
❏ wisselend per jaar
❏ anders, nl. .........................................................................................
15. Wat wordt er in uw FTO regelmatig behandeld?*
❏ indicaties en bijbehorende geneesmiddelen
❏ (plaatsbepaling) nieuwe geneesmiddelen
❏ NHG-standaarden
❏ een Formularium, namelijk dat van ...............................................
❏ automatisering
❏ substitutiebeleid of afleverbeleid
❏ patiëntenvoorlichting
❏ therapietrouw
❏ medicatiebewaking
❏ omgaan met druk van de patiënt om een middel
❏ doorverwijzingspatroon
❏ magistrale receptuur
❏ (overheids)maatregelen (incl. zorgverzekeraars)
❏ anders, nl. .........................................................................................
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16. Welke criteria spelen een rol bij de keuze van een onderwerp?*
❏ actualiteit
❏ interesse van de huisartsen
❏ interesse van de apothekers
❏ complexiteit van een onderwerp
❏ prescriptieverschillen
❏ te behalen kwaliteitswinst (goedkoper,minder,beter)
❏ bestaan NHG-standaard
❏ beschikbaarheid deskundigheidsbevorderingspakket WDH
17. Welke bronnen gebruikt u voor het FTO?*
❏ Geneesmiddelenbulletin
❏ Pharmaceutisch Weekblad
❏ Nederlands Tijdschrift voor Geneeskunde
❏ Huisarts en Wetenschap
❏ Medisch Farmaceutische Mededelingen
❏ Farmacotherapeutisch Kompas
❏ NHG-Standaarden
❏ Informatorium Medicamentorium
❏ "Adviezen voor farmacotherapie"
❏ Farmaceutische industrie
18. Welke geneesmiddelengroepen/indicaties zijn het afgelopen jaar besproken?
19. Wordt er in het FTO gewerkt aan een eigen formularium?
❏ nee, reden: .........................................................................................
❏ ja
20. Wordt er in het FTO gewerkt met een bestaand formularium?
❏ nee
❏ ja, nl. ..................................................................................................
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21. Geven de artsen tijdens het FTO een beschrijving van het eigen 
voorschrijfpatroon, als dit van toepassing is?
❏ nee, reden: .........................................................................................
❏ ja
❏ soms
❏ niet van toepassing
22. Worden de FTO-bijeenkomsten vastgelegd d.m.v. :
❏ verslagen
❏ besluiten-/afsprakenlijst
❏ niet
23. Hoe komt men tot een concrete afspraak?
❏ de voorzitter deelt mee wat er gedaan wordt
❏ na discussie wordt gekomen tot een (meestal) unaniem besluit
❏ anders, nl. .........................................................................................
24. Is het altijd duidelijk of, en zo ja wat, er is besloten?
❏ nee, reden: ........................................................................................
❏ ja
25. Wordt er tijdens het FTO gebruik gemaakt van:
❏ een notulist(e)
❏ audiovisuele hulpmiddelen
❏ reklame materiaal
❏ presentatie van derden
❏ anders, nl. .........................................................................................
26. Zijn er bepaalde zaken te benoemen die uw FTO-groep nodig heeft of 
kan gebruiken om de kwaliteit van het overleg te verbeteren?
❏ nee
❏ ja, nl. .................................................................................................
27. Wat verwacht uw FTO-groep van het terugkoppelen van prescriptie gegevens?*
❏ prikkeling
❏ startpunt voor een discussie
❏ inzicht van de arts in eigen prescriptie
❏ presenteren van spiegelinformatie over het voorschrijfgedrag
ter ondersteuning van het FTO
❏ toetsen van het werkelijke gedrag aan de voornemens
28. Op welke manier bent u van plan prescriptieterugkoppeling gegevens te gebruiken?
❏ start discussie/illustratie/prikkeling
❏ vergelijken van artsen
❏ bespreken van het effect
❏ anders, nl. .........................................................................................
29. Is er contact met andere FTO-groepen?
❏ nee, reden: ........................................................................................
❏ ja, op welke manier .........................................................................
30. Is er contact met de tweede lijn?
❏ nee, reden: ........................................................................................
❏ ja, op welke manier .........................................................................
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